Explor Drug Sci EDS Exploration of Drug Science 2836-7677 Open Exploration Publishing 10.37349/eds.2025.1008116 1008116 Review Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024) Aliashrafzadeh Hassan Writing—review & editing 1 Liu Dewey Writing—review & editing 1 De Alba Samantha Writing—review & editing 1 Akbar Imad Writing—review & editing 2 Lui Austin Writing—review & editing 1 Vanleuven Jordan Writing—review & editing 1 Martin Ryan Writing—review & editing 1 3 https://orcid.org/0000-0001-5659-0036 Wang Zhang Writing—review & editing 4 5 https://orcid.org/0000-0002-3934-9651 Liu Da Zhi 1 6 * Albericio Fernando Academic Editor University of KwaZulu-Natal, South Africa, Universidad de Barcelona, Spain 1Department of Neurology, University of California, Davis, CA 95616, USA 2Ayub Medical College, Abbottabad 22020, Pakistan 3Department of Neurological Surgery, University of California, Davis, CA 95616, USA 4Institute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616, USA 5Department of Chemistry, University of California, Davis, CA 95616, USA 6Mirnova Therapeutics, Inc., Davis, CA 95618, USA *Correspondence: Da Zhi Liu, Mirnova Therapeutics, Inc., Davis, CA 95618, USA. djliu@mirnovatherapeutics.com 2025 01 07 2025 3 1008116 05 02 2025 27 05 2025 © The Author(s) 2025. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Since our previous summary of the 74 FDA-approved kinase inhibitors in clinical and preclinical trials for non-cancerous neurological treatment, the US FDA has approved 13 additional kinase inhibitors since early 2022. This update incorporates new evidence for the now 87 FDA-approved kinase inhibitors in clinical and preclinical trials for the treatment of non-cancerous neurological disorders. By the end of October 2024, nearly all 87 FDA-approved kinase inhibitors have been tested in various animal models of non-cancerous neurological disorders, with twenty entered into clinical trials and six used for off-label treatments of neurological conditions in humans. Considering the challenges posed by intellectual property (IP), legal considerations, and limited blood-brain barrier (BBB) permeability, which may restrict some FDA-approved kinase inhibitors from effectively targeting the central nervous system (CNS), we further discuss the feasibility of designing novel proprietary analogs with enhanced BBB penetration to improve their therapeutic potential in neurological disorders. The new drugs typically retain full IP rights and remain costly; while repurposing kinase inhibitors may provide effective and affordable treatments for non-cancerous neurological disorders.

 Kinase inhibitors aberrant cell cycle clinical trials preclinical experiments neurological disorders NIH/NINDS R01NS089901] and [R01NS114061 Introduction

We developed an original concept of “Aberrant Cell Cycle Disease (ACCD)”, revealing that two major types of diseases (cancers and neurological diseases) share the same mechanism of “aberrant cell cycle re-entry” [1]. The aberrant cell cycle is implicated in both the unlimited proliferation of tumor cells in cancers and the post-mitotic death of mature neurons in non-cancerous neurological disorders [1–3]. Considering that aberrant cell cycle re-entry is manifested as oncogenic kinase activation and/or tumor suppressor activation, the cell cycle arrest (e.g., inhibiting oncogenic kinase, elevating tumor suppressors) that is widely practiced for cancer treatment can be leveraged for the treatment of non-cancerous neurological disorders.

Given human genome encodes ~500 protein kinases and a single kinase often has tens of artificial/synthetic inhibitors, there are likely thousands of synthetic kinase inhibitors. Among those, the FDA has approved a total of 87 kinase inhibitors, mostly for cancer therapy by the end of October 2024, with 74 approved by 2021 and 13 thereafter (i.e., abrocitinib, capivasertib, others) (Supplementary material). Unlike cancer drug development, the advancement of neurologically effective drugs for human use has seen limited success, despite neurological disorders being life-threatening and impacting millions of people worldwide each year [4–6]. Utilizing the ACCD concept, we previously reviewed the 74 kinase inhibitors that the FDA had approved by 2021 [2], summarizing their clinical and preclinical applications for neurological disorders and assessing their potential for repurposing in non-cancerous neurological treatments.

In this update, we incorporate new evidence of using the FDA-approved kinase inhibitors for non-cancerous neurological treatment. In addition to intellectual property (IP) and legal matters, the poor blood-brain barrier (BBB) permeability of some kinase inhibitors limits the repurposed use for neurological treatment, except for acute brain injuries [e.g., traumatic brain injury (TBI), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH)] that are characterized by immediate BBB disruption. To overcome these barriers, this review also discusses the strategy of structure modification of FDA-approved kinase inhibitors to synthesize new compounds of full IP and improved BBB permeability for the treatment of non-cancerous neurological disorders. We searched each individual kinase inhibitor with each subtype of neurological disorder in the databases (https://pubmed.ncbi.nlm.nih.gov; https://clinicaltrials.gov) for published preclinical experiments, clinical trials, and off-label use of the 87 FDA-approved kinase inhibitors for neurological treatments. Of note, non-FDA-approved kinase inhibitors and neurological cancers (e.g., glioblastoma, brain metastasis from peripheral cancers, neuroblastoma) are beyond the scope of this review.

 Kinase, kinase inhibitors, and FDA-approved kinase inhibitors and indications

Kinases, existing universally in various species, have predominantly been thought as oncogenes involving tumorigenesis for many decades [7, 8], in spite of the opposite evidence that shows several kinases [e.g., protein kinase C (PKC), mitogen-activated protein kinase kinase 4 (MAPKK4/MEK4), and death-associated protein kinase 3 (DAPK3)] function as tumor suppressors [7]. Kinases catalyze various reactions of phosphorylation where the high-energy molecules (e.g., ATP) donate phosphoryl groups to substrate molecules [9, 10], with approximately 13,000 human proteins having phosphorylation sites [11]. The transfer of the phosphoryl group from one molecule to another is a fundamental process in many aspects of metabolism, gene regulation, signal transduction, and others [12]. Regarding target substrates, human protein kinases are classified into three types: serine-threonine kinases (STKs), tyrosine kinases (TKs), and dual specificity kinases (STKs/TKs). According to the presence or absence of transmembrane receptor structure, TKs are further divided into receptor TKs (RTKs) and non-RTKs (NRTKs).

There are an estimated thousands of synthetic kinase inhibitors, as the human genome encodes ~500 protein kinases while a single kinase often has tens of artificial/synthetic inhibitors. For example, Src kinase has an increasing list of its synthetic inhibitors: dasatinib, bosutinib, saracatinib, WH-4-023, ENMD-2076, PP1, PP2, pelitinib, ponatinib, PP121, tirbanibulin, SU6656, repotrectinib, UM-164, apatinib, eCF506, elzovantinib, DGY-06-116, 1-NM-PP1, TPX-0046, TL02-59, other.

As for the non-FDA-approved kinase inhibitors, it was reported that bruton TK (BTK) inhibitors (i.e., evobrutinib, fenebrutinib, orelabrutinib, remibrutinib, tolebrutinib) had been tested in clinical trials for treatment of multiple sclerosis (MS) [13]. In addition, a number of non-FDA-approved kinase inhibitors have shown efficacy for the treatment of neurological disorders in experimental models, such as Src family kinase (SFK) inhibitors (PP2, saracatinib) [14–18], rho-associated protein kinase (ROCK) inhibitor (Y-27632) [19–21], extracellular signal-regulated kinase (ERK) inhibitor (PD98059) [22], cyclin-dependent kinases (CDKs) inhibitors (flavopiridol, roscovitine) [23–27], and others. Therefore, many kinase inhibitors (whether FDA-approved or not) can be used to treat both cancers and neurological disorders, which in turn strongly supports the ACCD concept that cancers and neurological disorders share similar underlying pathophysiological mechanisms.

 Clinical trials of FDA-approved kinase inhibitors for neurological treatment

Many of the FDA-approved kinase inhibitors have been tested in clinical and preclinical trials for neurological disorders, though none of them have been approved by the FDA for neurological treatments (Supplementary material). Acalabrutinib, a BTK inhibitor, is currently undergoing investigation in a phase II clinical trial (NCT05065554) to assess the safety and efficacy of its combination with rituximab or other CD20 antibodies for individuals suffering from neuropathies associated with immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MGUS) or Waldenstrom macroglobulinemia (WM). Alpelisib, an inhibitor of PI3K, is in an ongoing phase II clinical trial (NCT05577754) in pediatric and adult patients with megalencephaly-capillary malformation polymicrogyria syndrome (MCAP).

Baricitinib, classified as a JAK inhibitor, has finished a phase II trial (NCT03921554) and is presently being evaluated in a phase II/III trial (NCT04517253) focused on determining the safety and efficacy of baricitinib for Aicardi-Goutieres syndrome (AGS), a genetic disorder that results in profound mental and physical disabilities in infants. This drug was studied in a phase I/II trial (NCT05792462) assessing the efficacy and safety of baricitinib in neuromyelitis optica spectrum disorders (NMOSD). In another phase III trial (NCT06631287) in patients with long COVID, baricitinib was studied to determine if it can improve neurocognitive function, measures of physical function, quality of life, post-exertional malaise, the effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures. The effect of baricitinib administration on the outcome of participants with moderate and severe traumatic ICH/contusions was studied in a phase II clinical trial (NCT06065046). In another trial (NCT04378621), the anti-inflammatory effect of baricitinib was investigated on neuropsychiatric symptoms and morphological changes in the brain caused by rheumatoid arthritis (RA). Other ongoing trials include phase II/III trials (NCT06548802) assessing the efficacy and safety of baricitinib in patients with pulmonary injury after ICH, and a phase II study (NCT05452564) evaluating the efficacy and safety of baricitinib for the reduction of human immunodeficiency virus (HIV) in the central nervous system (CNS). In addition, the role of this drug in CNS mechanisms of anhedonia and psychomotor slowing in depressed people with HIV was investigated in a phase II trial (NCT05849038). Lastly, a phase I/II trial (NCT05189106) assessed the safety of baricitinib in Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). There is also a case report describing positive effects of baricitinib for the treatment of ocular myasthenia gravis (MG) in a 58-year-old woman who received baricitinib for alopecia areata [28]. The effects of baricitinib, empagliflozin, linagliptin, and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes were studied in a randomized, crossover trial [29]. The drug bosutinib, known for its inhibitory effects on Src and BCR-ABL, has been the focus of multiple clinical trials addressing various neurodegenerative disorders. Among these trials is a phase I study (NCT04744532) evaluating its application in ALS, along with another ongoing phase I trial (NCT02921477) that investigates its potential benefits for dementia and mild cognitive impairment. Moreover, a completed phase II trial (NCT03888222) has specifically targeted Lewy body dementia (LBD).

In a phase II trial (NCT04079179), Cobimetinib, known for its role as a MAPKK/MEK inhibitor, has been researched for its safety and efficacy in addressing histiocytic disorders that could potentially lead to neurodegeneration. Dasatinib, which acts as an inhibitor of BCR-ABL, Kit, Src, EphA2, EGFR, and PDGFR, has been evaluated in combination with quercetin, a flavonoid recognized for its anti-inflammatory and antioxidant characteristics, in multiple completed trials (NCT04063124 phase I and II, NCT05422885 phase I and II) and is currently under investigation in ongoing trials (phase I and II in NCT04785300, phase II in NCT04685590) for the management of mild cognitive impairment and AD [30, 31]. Extensive clinical trials have investigated Everolimus, an agent that acts as an inhibitor of both FKBP and mTOR, in relation to different types of acute brain injuries, as well as neurodegenerative and neurodevelopmental disorders. Such instances include the completion of NCT03198949 (a phase II trial) of Everolimus for epilepsy and focal cortical dysplasia (FCD), and another completed phase I/II trial (NCT02991807) of Everolimus for hamartoma tumor syndrome. A phase II trial (NCT01997255) that is presently underway is assessing the safety and efficacy of Everolimus for patients experiencing seizures linked to Sturge-Weber syndrome. A total of twelve studies, which include both finished and current trials, are examining the safety and efficacy of Everolimus for patients suffering from tuberous sclerosis complex (TSC), which is commonly connected with FCD, cognitive disabilities, autism, intractable seizures, self-injurious behavior, and a range of other neurocognitive challenges (NCT01070316, NCT01713946, NCT02451696, NCT01929642, NCT01289912, NCT02962414, NCT01730209, and NCT01954693), and a terminated phase II clinical trial study (NCT00857259) evaluated the safety profile and therapeutic efficacy of Everolimus, used alone or alongside ranibizumab, in patients affected by neo-vascular age-related macular degeneration. Imatinib, which acts as an inhibitor of Kit, BCR-ABL, and PDGFR, has been studied in various acute brain injury conditions as well as neurodegenerative diseases. A phase III clinical trial (NCT03639922) evaluated the addition of Imatinib to standard acute stroke treatment, focusing on its potential to enhance functional recovery. Furthermore, a phase II clinical trial (NCT02363361) is examining the safety, absorption, and tolerability of Imatinib in individuals with cervical spinal cord injury (SCI). A separate phase II clinical trial (NCT03674099) is currently evaluating Imatinib as an innovative treatment for MS, assessing its effectiveness in comparison to methylprednisolone, which is the standard treatment for relapses of MS. Additionally, there was an intended phase I clinical trial (NCT00403156) that aimed to explore the application of Imatinib in the treatment of choroidal neovascularization; however, this study has been retracted. Nilotinib functions as a kinase inhibitor, targeting the activities of PDGFR, BCR-ABL, and DDR1. It has undergone investigation into various neurodegenerative disorders through clinical trials. Currently, a phase II trial (NCT04002674) is exploring Nilotinib’s effects on patients with dementia with Lewy bodies, focusing on pharmacokinetics, tolerability, biomarkers, and safety. Also, a phase I trial (NCT03764215) involved administering Nilotinib to individuals diagnosed with Huntington’s disease (HD). The study evaluated biomarkers, including levels of phosphorylated tau, alongside functional outcomes. Currently, a phase III clinical trial (NCT05143528) is underway to assess the safety and effectiveness of Nilotinib in early AD patients, utilizing two distinct dosages. A phase II clinical trial (NCT02947893) investigated the effectiveness of Nilotinib in individuals diagnosed with AD. The study specifically measured the impact of Nilotinib on cell death using various cell markers. Additionally, the concentrations of amyloid in the brain were evaluated through positron emission tomography (PET) imaging. Furthermore, there are three trials, both completed and ongoing, that focus on the effects of Nilotinib in patients with Parkinson’s disease (PD) (NCT03205488, NCT02954978, and NCT02281474). Pazopanib, an inhibitor of PDGFR α/β, FGFR 1/3, VEGFR 1/2/3, Itk, Lck, Fms, and Kit, has been tested in multiple completed or terminated trials (NCT01154062, NCT00659555, NCT00612456, NCT00463320, NCT01072214, NCT01134055, NCT01051700, NCT01362348, and NCT00733304) for macular degeneration. Pirtobrutinib, a BTK inhibitor, was studied in a phase II clinical trial to assess its efficacy and safety in participants with MS (NCT06104683), though the trial has been withdrawn. Regorafenib, a VEGF kinase inhibitor, successfully passed phase I trial for neovascular age-related macular degeneration. The phase IIa trial study (NCT02222207) was terminated as its results did not meet the effectiveness of the current standard of care [32].

Sirolimus, which functions as an mTOR inhibitor and was first used as an immunosuppressant in kidney transplants, has been incorporated into various clinical trials targeting neurological and psychiatric conditions, including epilepsy (NCT03486366, NCT03646240), cerebral aneurysms (NCT04141020), age-related macular degeneration (NCT02732899, NCT01445548, NCT00766649, NCT01675947, NCT00712491, NCT00304954, NCT02357342, and NCT00766337), AD (NCT04629495, NCT06022068, and NCT04200911), ALS (NCT03359538), frontotemporal dementia (NCT04408625), MS (NCT00095329), PD (NCT04127578), refractory epilepsy (NCT05613166) multiple system atrophy (MSA) [33], (NCT03589976), diabetic retinopathy (NCT00711490), diabetic macular edema (NCT00401115 and NCT00656643), Sturge-Weber syndrome (NCT03047980, NCT02080624), TSC (NCT05104983, NCT04595513, NCT02061397, NCT01929642, and NCT00490789), Lysosomal diseases (NCT03952637), Leigh syndrome (LS) (NCT03747328), Gaucher disease type 2 (NCT04411654), alcohol use disorder (NCT03732248), smoking cessation (NCT04161144), depression (NCT02487485), stroke prevention (NCT04948749), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (NCT06257420), communicating hydrocephalus secondary to ICH (NCT06563817), post-traumatic stress disorder (PTSD) (NCT01449955), surgically refractory epilepsy (NCT03646240), extracranial vertebral artery stenosis (NCT05885932), ischemic stroke (IS) (NCT02578069), intracranial atherosclerotic stenosis (NCT05719883, NCT06614972, and NCT04949880), and mild cognitive impairment (NCT04200911).

Overall, in the context of clinical trials, four of them have successfully completed phase I (NCT00401115, NCT03732248, NCT03646240, and NCT04200911). Fourteen trials have advanced to complete phases I/II or II (NCT01445548, NCT02357342, NCT02732899, NCT00766649, NCT00304954, NCT02080624, NCT01929642, NCT00656643, NCT04161144, NCT02487485, NCT02061397, NCT00711490, NCT03359538, and NCT04595513). One trial has successfully concluded in phase II/III (NCT03047980), six trials have been withdrawn or terminated during phases I/II (NCT00095329, NCT01675947, NCT03589976, NCT00712491, NCT00766337, and NCT03747328), two trials are currently in phase II with an unknown status (NCT00490789, NCT05613166). As a TK inhibitor, sunitinib has been evaluated in two completed phase I/II trials targeting neovascular age-related macular degeneration (NCT03249740) and diabetic macular edema associated with retinal vein occlusion (NCT04085341). Temsirolimus, known for being a prodrug of sirolimus, inhibits the mTOR signaling pathway, has a completed phase II trial for the treatment of relapsing-remitting MS (NCT00228397). Tofacitinib, known for its role as a Janus kinase enzyme inhibitor, has been involved in multiple clinical trials. one of which is an ongoing phase I trial for MG patients (NCT04431895). An early phase I clinical trial (NCT06689982) explored the potential of tofacitinib in treating ALS and also a terminated phase I/II clinical trial of tofacitinib focused on treatment-resistant depression (NCT04141904). Another completed phase II trial focused on the application of tofacitinib in individuals with Down syndrome (DS) to address various skin conditions, including alopecia areata, atopic dermatitis/eczema, and psoriasis (NCT04246372). Trametinib, a MEK inhibitor, was used in a terminated phase I/II clinical trial for ALS (NCT04326283). Upadacitinib, a JAK1 selective inhibitor, is currently going through a phase III trial investigating its use in the treatment of giant cell arteritis (NCT03725202), comparing the efficacy of upadacitinib plus corticosteroids versus corticosteroids alone. Zanubrutinib, a BTK inhibitor, is being tested in an ongoing phase II trial (NCT05356858) for the treatment of NMOSD, a medical condition characterized by the immune system’s attack on the optic nerves and spinal cord. The clinical trial demonstrated that BTK activity is increased in both B cells and microglia, indicating that this medication plays a role in improving the pathology associated with NMOSD [34].

 Off-label use of FDA-approved kinase inhibitors for neurological treatment

Although the FDA has not approved any kinase inhibitors for the treatment of neurological disorders, several FDA-approved kinase inhibitors have been used off-label. For example, Everolimus has been documented for the treatment of patients with TSC-associated refractory seizures [35], epilepsy [36], hemimegalencephaly-related epilepsy [37], pediatric TSC-related epilepsy [38], and FCD [39]. Ibrutinib has been used for the treatment of patients with white matter injury from graft-versus-host disease (GVHD) [40], anti-myelin-associated glycoprotein neuropathy [41], and MS [42], while Imatinib has been used for the treatment of patients with BBB malfunction in DiGeorge syndrome [43], and in IS [44]. With mixed results, ruxolitinib and baricitinib were recently used in the treatment of AGS, an immune-mediated neurological disease refractory to conventional immunosuppression [45]. Tofacitinib has also been reported in the treatment of refractory autoimmune encephalitis, again with mixed results [46].

 Preclinical trials of FDA-approved kinase inhibitors for neurological treatment

A total of 20 FDA-approved kinase inhibitors have undergone evaluation in clinical trials focused on neurological disorders; however, there exists a significant number of preclinical investigations examining the impact of these FDA-approved kinase inhibitors on neurological conditions. Research has been conducted on abemaciclib in preclinical settings to explore its potential for treating motor neuron degeneration [47], PTSD [48], and AD [49, 50]. Abrocitinib, an inhibitor of JAK1, JAK2, JAK3, and Tyk2, has been investigated for its neuroinflammation and neuroprotective effects on TBI [51]. In preclinical studies, Afatinib has been assessed for its potential to treat neuroinflammation resulting from a lack of oxygen and glucose [52], MS [53], nicotine dependence [54], TSC [54], and cortical brain injuries [55]. The efficacy of Axitinib has been investigated as a possible treatment option for AD [56], IS [57, 58], and diabetes-induced neuropathy [59]. The potential of Alectinib as a therapeutic intervention for binge drinking has been explored [60, 61] and IS [62]. Preclinical studies have investigated the use of baricitinib as a potential therapeutic option for neurocognitive disorders resulting from HIV infection [63], encephalitis [64, 65], MS [65], hypersensitivity in DS [66], SCI [67], Hutchinson-Gilford progeria [68], AD [69–71], AGS [72–75], ALS [76], neuropathic pain [77], type 1 diabetes mellitus peripheral neuropathy and bone denervation [78] and chronic itching induced by frontal cortex neurons [79]. Research conducted in a preclinical setting suggests that Binimetinib could be a viable treatment for specific variants of AD [80]. The efficacy of Bosutinib has been investigated as a possible treatment option for ICH [81], cerebral ischemia [82], PD [83–86], AD [87], transactive response DNA binding protein 43 (TDP-43) pathology [88], stress-activated protein kinase interacting protein 1 (SIN1)-mediated neurotoxicity [89], botulinum neurotoxins [90], LBD [91, 92], and ALS [93–95]. Cabozantinib has undergone evaluation for its potential use in treating Rett syndrome (RTT) [96], and AD [97–99]. Crizotinib has undergone evaluation for its potential use in treating PD [100], AD [101], persistent pain [102], Toxoplasma gondii [103], and the condition known as craniosynostosis, which is associated with Saethre-Chotzen syndrome, involves the early closure of sutures in the skull, potentially resulting in abnormal head shapes and neurological complications [104].

Research has been conducted on Dabrafenib to assess its viability as a treatment of IS [105], SCI [106], PD [107, 108], ataxia caused by neurohistiocytosis of the cerebellum [109], and brain arteriovenous malformation (BAVM) [110]. Dasatinib has been tested for the potential treatment of lipopolysaccharide (LPS)-induced neuroinflammation [111], kainic acid-induced neuroinflammation [112], glaucoma [113], tau‐associated pathology [114], MS [115], ALS [116–118], PD [117], cognitive dysfunction [119, 120], obesity-induced anxiety [121], chronic unpredictable stress that can induce cognitive deficits [122], fetal alcohol syndrome [123], botulinum neurotoxins [90], AD [124], endotoxemia [125], and IS [126]. In combination with quercetin, Dasatinib has been reported for treatment of tauopathy [127], seizure [128, 129], cognitive deficits [130, 131], TBI [132], AD [133–137], TBI [138], motor neuron disease [118], and brain aging models [139–143]. Deucravacitinib, a selective Tyk2 inhibitor, has been proven to inhibit monocyte activation [144], which may be useful in treating neuroinflammation. Research has been conducted on Duvelisib to assess its effectiveness in addressing peripheral neuropathy caused by Paclitaxel [145]. Erlotinib has undergone evaluation for its potential use in treating nerve fiber damage [146], intracranial aneurysm formation [147], ALS [148], diabetic peripheral neuropathy [149, 150], and memory loss [151]. The efficacy of Everolimus has been investigated as a possible treatment for encephalopathy of prematurity [152], atherosclerosis-associated brain hypoxia [153], IS [154–156], AD [157, 158], HD [159, 160], vascular dementia [161], LPS-induced neuroinflammation [162], insulin-dysfunction-related cognitive dysfunction [163], glutamate-induced neurotoxicity [164], Guillain-Barre’ syndrome [165], MS [166], TSC-associated autism-like social deficits [167, 168], Lafora disease [169], TSC-related epileptic encephalopathy [170–173], ICH [174], white matter injury [175], and hyperthermia-induced seizures [176] and neuroinflammation associated with seizures [177, 178].

Fedratinib has been evaluated for the potential treatment of IS [179], ICH [180], Wernicke’s encephalopathy [181, 182], and AD [183]. Fostamatinib was recently examined in experimental models for the treatment of schizophrenia [184] and ALS [185]. As a highly selective inhibitor, Fruquintinib specifically targets the TKs VEGFR 1, VEGFR 2, and VEGFR 3, has been carried out to assess the potential treatment options for cerebral amyloid angiopathy (CAA) [186]. The efficacy of gefitinib has been investigated as a possible treatment for SCIs [187], amyloid-β-induced memory loss [151], schizophrenia [188], Streptococcus pneumoniae meningitis [189], Toxoplasma gondii (that is capable of inducing symptoms that are characteristic of congenital neurological conditions and meningoencephalitis) [103, 190], IS [191], AD [192], and epilepsy [193].

The efficacy of Ibrutinib has been assessed in relation to the treatment of IS [194, 195], SCI [196, 197], age-related cognitive deterioration [198], AD [98, 199, 200], LPS-induced neuroinflammation [201], anxiogenic behavior [202], depression [203, 204]. Cocaine use disorder [205], SAH [206], and ALS [207]. Imatinib has been tested for the potential treatment of SAH [208–213], ICH [214–218], cerebral small vessel disease [219], TBI-induced seizure [220], seizures [220–222], TBI [223], IS [224–226], AD [227–244], PD [245–250], prion diseases [251–254], ALS [255], HD [256], cerebral malaria [257], Hypoxic ventilatory depression (that is characterized by a diminished ventilatory response triggered by hypoxemia, or low oxygen levels in the blood) [258], Niemann-Pick type C disease [259], Niemann-Pick type A disease [260], Gaucher disease [261], simian HIV encephalitis [262], morphine tolerance [263], BBB dysfunction in chronic cerebral hypoperfusion [264], and glutamate-induced oxidative injury [265]. Infigratinib has been evaluated as a prospective treatment option for diabetic retinopathy [266] and MS [267].

Lapatinib has been assessed for the potential treatment of epilepsy [268], organophosphate induced axonal damage in the spinal cord (it highlights the potential for neurotoxic effects that can compromise motor function and overall neural health) [269], AD [270, 271], PD [272], and BBB disruption in SARS-CoV-2 [273]. The efficacy of Lorlatinib has been investigated as a possible treatment option for persistent pain [102]. Midostaurin has been assessed for the potential treatment of traumatic SCI [274] and AD [275]. Neratinib has been tested for the potential treatment of AD [276, 277]. Netarsudil has been tested for the potential treatment of optic nerve degeneration [278]. Nilotinib has been tested for the potential treatment of Epileptic seizures [279], tauopathies [83, 84, 280], alpha-synucleinopathies [84, 281–283], TDP-43 pathology [85, 88], Beta-amyloid pathology [280], AD [69, 284–286], PD [287–289], chorea-acanthocytosis [290, 291], Niemann-Pick type A disease [260], LPS-induced cognitive impairment and neuroinflammation [292].

Pacritinib, an inhibitor of JAK1, JAK2, JAK3, and Tyk2, has been used to explore the potential interventions for RTT [293], HIV-associated neurological disorders, and also neurodegenerative diseases [294]. The efficacy of Palbociclib has been investigated as a possible therapeutic option for Spinal Muscular Atrophy (SMA) [295], amyloid beta-peptide pathology [296], and PD [297]. Research has been conducted on pazopanib to assess its efficacy in the treatment of tauopathy [298], neurodegeneration-induced memory and cognitive deficits [299], osteoarthritis pain [300], PD [301, 302], and AD [303]. Pexidartinib has been tested for the potential treatment of ICH [304–306], SAH [307], obesity-related cerebrovascular dysfunction [308], cognitive decline due to brain damage [309], tauopathy [310], AD [311, 312], HD [313], MS [314–316], spinocerebellar ataxia type 1 (SCA1) that is a genetic, neurodegenerative disorder that primarily affects the cerebellum [317], DS (also known as trisomy 21) [318], peripheral nerve injury induced mechanical hypersensitivity (also known as allodynia or hyperesthesia) [319], cocaine addiction [320], PD [321–323], psychiatric disorders like schizophrenia [324], cerebellar ataxias [325], LS [326, 327], opioid use disorder [328], psychiatric disorders such as depression [329], TBI [330], and neuropathic pain [331]. Ponatinib has been assessed for the potential treatment of IS [332], epilepsy [333], and cerebral cavernous malformation (abnormal blood vessel clusters within the brain may result in various neurological manifestations, including seizures, headaches, and the potential for stroke) [334]. Regorafenib has been assessed for the potential treatment of AD [335]. The efficacy of Ruxolitinib has been investigated as a possible treatment option for PD [336], MS [337–339], DS [340], dysfunction of the BBB induced by cytokines [341], HIV-related neurocognitive disorders [342], depressive-like behaviors and cognitive impairments [343], TBI [344, 345], IS [346], SCI [347, 348], AD with TDP-43 inclusions [70], and COVID-19 induced peripheral and CNS disease [349].

Selumetinib has been tested for the potential treatment of frontotemporal lobar degeneration [350], obsessive-compulsive disorder [351], acrolein-induced neurotoxicity [352], and ICH [353]. Sirolimus has been assessed for the potential treatment of IS [154, 354–388], TBI [389–396], SAH [397–403], SCI [404–415], germinal matrix hemorrhage (GMH) [416, 417], ICH [418–420], seizure-induced memory deficits [421–424], seizure in LS [425], spinal cord ischemia [426, 427], preganglionic cervical root transection [428], optic nerve crush [429], alveolar nerve transection [430], ischemic retinal disease [431], MS [432–442], PD [443–446], cerebral palsy (CP) [447], prion disease [448–450], AD [451–455], vascular dementia (that is a type of cognitive impairment that occurs due to reduced blood flow to the brain) [456], diabetes-related pathology that mimics AD [457], diabetes-induced neuropathology [458], HD [459–464], macular degeneration [465], optic nerve degeneration [466], neurodegeneration of retina [467], cadmium-induced neurodegeneration [468–471], spiral ganglion neurons degeneration [472], tauopathy [473, 474], synucleinopathy [475–477], MG [478, 479], iron-induced cognitive impairments [480], cognitive impairments resulting from intermittent hypoxia [481], cognitive impairments resulting from cannabinoid exposure [482], diabetic perioperative neurocognitive disorders [483], ethanol-induced neurodegeneration [484], neurodegeneration associated with aging [485], methylmercury-induced neurotoxicity [486], TDP-43 proteinopathy [487], ALS [488], autism spectrum disorder (ASD) [489–496], autism-associated behavioral disorders [497], Krabbe disease [498], trisomy 21 [499–502], intellectual disability [503], fetal alcohol spectrum disorders [504–506], autism linked to TS [507–510], TSC [511–514], TSC-associated neuropsychiatric disorders (TAND) [515], neurodevelopmental defects in TSC [516, 517], cognitive deficits in TSC [518, 519], Koolen-de Vries syndrome (that is a hereditary condition marked by delays in development, cognitive impairments, and unique facial characteristics) [520], FCD [521], Schaaf-Yang syndrome [522], cerebral malaria [523–525], neuropathic pain [526], seizure-induced anxiety [527], anxiety disorders [528–530], obesity-induced anxiety and depression [531], diabetes mellitus-related cognitive deficits [532–534], nicotine addiction [535], alcohol-related disorders [516, 536, 537]. Herpes simplex virus encephalitis [538], mania [539], epilepsy [172, 540–543], epilepsy-induced anxiety and depression [544], porcine hemagglutinating encephalomyelitis virus [545], photochemical damage in retinal photoreceptor cells [546], multisystem proteinopathy [547], N-methyl-D-aspartate (NMDA)-induced retinal damage [548–550], adverse optineurin phenotypes [551], hydrocephalus [552], sleep disorders [553], depression [554], drug-seeking behavior [555–557], Inflammation of the nervous system resulting from aging [558], mitochondrial encephalopathy [559], TANC2 mutation-induced neuropsychiatric disorders [560], impact of general anesthesia on neurodevelopmental disorders in individuals with fragile-X syndrome [561]. The behavioral manifestations of depression and anxiety induced by H. pylori infection [562], epileptic brain injury [563], age-related hearing loss [564], MSA [565], brain hypervascularization [566], sepsis-induced cognitive impairment [567], polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome [568].

FCD type II induced epileptic seizures [569]. Sorafenib has been tested for the potential treatment of SAH [570], IS [571], SCI [572], AD [97, 573, 574], PD [575], MS [576, 577], rabies [578], Rift Valley fever (RVF) virus [579], alphaviruses [580], and picornavirus enterovirus 71 [581]. Sunitinib has been tested for the potential treatment of TBI [582], seizure [583], AD [584–587], RTT [96], cognitive impairment associated with HIV [588, 589], Dengue virus [590], rabies [591], and optic nerve injury [592].

Temsirolimus has been assessed for the potential treatment of SCI [410], PD [593, 594], tauopathy [595, 596], AD [597], SCA3 [598], nicotine withdrawal-associated cognitive deficits [599], and X-linked adrenoleukodystrophy (a genetic disorder primarily affecting the nervous system and adrenal glands) [600]. Tofacitinib has been evaluated for the potential treatment for IS [601], AD [602], MS [603, 604], PD [605], ALS [606], Venezuelan equine encephalitis virus (VEEV) [607], SCI [608], neuropsychiatric lupus (NPSLE) [609]. Trametinib has been tested for the potential treatment of TBI [610], aneurysmal SAH [611], BAVMs [612], ALS [613, 614], AD [615, 616], demyelinating disease [617]. Vandetanib has been tested for the potential treatment of GMH [618]. Vemurafenib has been tested for the treatment of laminin-α2-related congenital muscular dystrophy (LAMA2-CMD), which is a neuromuscular disease (LAMA2-CMD) [619].

 Structure modification for new chemical entities with improved BBB penetration

While repurposing FDA-approved kinase inhibitors for CNS disorders accelerates the clinical trials, early kinase inhibitors, which were often not developed to treat CNS disorders, exhibit limited selectivity and off-target side effects. Therefore, developing new BBB-penetrating chemical entities such as kinase inhibitors will provide a more targeted treatment of kinase-related CNS disorders. Because of the unique structure and function of the BBB, such as the tight junction and efflux pumps, small-molecule CNS drugs usually possess different structural features from non-CNS drugs from the medicinal chemistry perspective. For example, other than using Lipinski’s guidelines to design oral small-molecule drugs, Pfizer chemists have provided a more focused CNS multiparameter optimization (MPO) score to guide BBB-penetrating small-molecule discovery [620, 621]. The CNS MPO score evaluates a small molecule’s properties of cLogP (preferably < 3), cLogD (< 2), molecular weight (< 360), pKa (< 8), topological polar surface area (between 40 to 90), and the number of hydrogen-bond donors (< 2). Usually, a CNS MPO score of four or above indicates a higher probability of BBB penetration. It is a common strategy in drug discovery to improve the physiological properties of existing non-BBB-penetrating drugs by structural modifications so that the new chemical entities possess better BBB permeability. In this way, a therapeutic concentration can be reached in the CNS while the plasma concentration is maintained relatively low. In the next paragraph, we highlight some recent developments in CNS-penetrating kinase inhibitors that originate from FDA-approved drugs.

Erlotinib, a first-generation EGFR inhibitor with a low BBB penetration and an unbound brain-to-plasma partition coefficient (Kp,uu,brain) of 0.05, was approved in the US to treat non-small cell lung cancer and pancreatic cancer. Structural optimization of erlotinib led to the discovery of JCN037 which has substantially improved BBB penetration with a Kp,uu,brain of 1.30 [622]. The structural modifications include rigidification of the molecular architecture by shortening the water-exposed ether chain of erlotinib as well as replacing the alkyne group with a bromine atom to improve the BBB-penetration. Ibrutinib, the first FDA-approved BTK inhibitor for the treatment of multiple cancers, such as leukemia and lymphoma, cannot accumulate in the CNS due to drug efflux by P-glycoprotein (P-gp) [623]. However, structural modifications have resulted in a new molecule, tolebrutinib [624], which can effectively penetrate the BBB. The major structural difference between Ibrutinib and tolebrutinib is the hinge-binding group: Ibrutinib utilizes a pyrimidine substructure, and tolebrutinib employs a more lipophilic pyridine substructure. Additionally, the FDA-approved BRAFV600E inhibitor vemurafenib cannot cross the BBB, but after removing the flexible 4-chlorophenyl group and reducing the molecular weight, a new BRAFV600E inhibitor, PF-07284890 (ARRY-461), was developed with improved BBB penetration [625]. Its phase Ia/b clinical trial (NCT04543188) was terminated recently due to an internal business decision, but not major safety concerns or requests from any regulatory authorities. Lastly, AZD0156, an ataxia-telangiectasia mutated (ATM) kinase inhibitor, shows an efflux ratio of 23.7 in MDCKII-MDR1-BCRP assays and is unlikely to penetrate the BBB. By increasing the lipophilicity of AZD0156, a new compound, AZD1390, exhibited substantially increased BBB penetration with an efflux ratio of 1.8 in MDCKII-MDR1-BCRP assays, unlikely to engage the efflux pump [626].

 Conclusions

By the end of October 2024, nearly all 87 FDA-approved kinase inhibitors have been tested in various animal models of non-cancerous neurological disorders, with twenty entered into clinical trials and six used for off-label treatments for non-cancerous neurological disorders in humans. More kinase inhibitors are expected to enter the pipeline of clinical trials for neurological indications. As compared to the new drugs that typically retain full IP rights and remain costly, repurposing kinase inhibitors, if proven successful, could offer effective and affordable treatments for non-cancerous neurological disorders.

 Abbreviations ACCD

Aberrant Cell Cycle Disease

 AD

Alzheimer’s disease

 AGS

Aicardi-Goutieres syndrome

 ALS

amyotrophic lateral sclerosis

 BAVM

brain arteriovenous malformation

 BBB

blood-brain barrier

 BTK

bruton tyrosine kinase

 CNS

central nervous system

 DS

Down syndrome

 FCD

focal cortical dysplasia

 GMH

germinal matrix hemorrhage

 HD

Huntington’s disease

 HIV

human immunodeficiency virus

 ICH

intracerebral hemorrhage

 IP

intellectual property

 IS

ischemic stroke

 Kp,uu,brain

unbound brain-to-plasma partition coefficient

 LAMA2-CMD

laminin-α2-related congenital muscular dystrophy

 LBD

Lewy body dementia

 LPS

lipopolysaccharide

 LS

Leigh syndrome

 MAPKK4/MEK4

mitogen-activated protein kinase kinase 4

 MG

myasthenia gravis

 MPO

multiparameter optimization

 MS

multiple sclerosis

 MSA

multiple system atrophy

 NMOSD

neuromyelitis optica spectrum disorders

 PD

Parkinson’s disease

 PTSD

post-traumatic stress disorder

 RTKs

receptor tyrosine kinases

 RTT

Rett syndrome

 SAH

subarachnoid hemorrhage

 SCA1

spinocerebellar ataxia type 1

 SCI

spinal cord injury

 STKs

serine-threonine kinases

 TBI

traumatic brain injury

 TDP-43

transactive response DNA binding protein 43

 TKs

tyrosine kinases

 TSC

tuberous sclerosis complex

 Supplementary materials

Other supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1008116_sup_1.xlsx.

 Declarations Author contributions

HA, DL, SDA, IA, AL, JV, RM, and ZW: Writing—review & editing. DZL Conceptualization, Writing—review & editing, Funding acquisition. All authors have read and agreed to the published version of the manuscript.

 Conflicts of interest

Da Zhi Liu who is the Editorial Board Member of Exploration of Drug Science and Guest Editor of Leveraging the FDA-Approved Kinase Inhibitors to Treat Neurological Disorders had no involvement in the decision-making or the review process of this manuscript. The other authors declare no conflicts of interest.

 Ethical approval

Not applicable.

 Consent to participate

Not applicable.

 Consent to publication

Not applicable.

 Availability of data and materials

Not applicable.

 Funding

We acknowledge the support of NIH/NINDS grants [R01NS089901] and [R01NS114061] to DZL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

 Copyright

© The Author(s) 2025.

 Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

 Liu DZ Ander BP Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update ScientificWorldJournal 2012 2012 491737 10.1100/2012/491737 22547985 PMC3323905 Lui A Vanleuven J Perekopskiy D Liu D Xu D Alzayat O et al. FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders Pharmaceuticals (Basel) 2022 15 1546 10.3390/ph15121546 36558997 PMC9784968 Lui A Do T Alzayat O Yu N Phyu S Santuya HJ et al. Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders Pharmaceuticals (Basel) 2024 17 426 10.3390/ph17040426 38675388 PMC11054060 Dewan MC Rattani A Gupta S Baticulon RE Hung YC Punchak M et al. Estimating the global incidence of traumatic brain injury J Neurosurg 2018 130 1080 97 10.3171/2017.10.JNS17352 29701556 Feigin VL Brainin M Norrving B Martins S Sacco RL Hacke W et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022 Int J Stroke 2022 17 18 29 10.1177/17474930211065917 34986727 Corriveau RA Bosetti F Emr M Gladman JT Koenig JI Moy CS et al. The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline Cell Mol Neurobiol 2016 36 281 8 10.1007/s10571-016-0334-7 27095366 PMC4859348 An E Brognard J Orange is the new black: Kinases are the new master regulators of tumor suppression IUBMB Life 2019 71 738 48 10.1002/iub.1981 30548122 PMC6563145 Du Z Lovly CM Mechanisms of receptor tyrosine kinase activation in cancer Mol Cancer 2018 17 58 10.1186/s12943-018-0782-4 29455648 PMC5817791 Berndt N Karim RM Schönbrunn E Advances of small molecule targeting of kinases Curr Opin Chem Biol 2017 39 126 32 10.1016/j.cbpa.2017.06.015 28732278 PMC5728163 Fabbro D Cowan-Jacob SW Moebitz H Ten things you should know about protein kinases: IUPHAR Review 14 Br J Pharmacol 2015 172 2675 700 10.1111/bph.13096 25630872 PMC4439867 Vlastaridis P Kyriakidou P Chaliotis A Van de Peer Y Oliver SG Amoutzias GD Estimating the total number of phosphoproteins and phosphorylation sites in eukaryotic proteomes Gigascience 2017 6 1 11 10.1093/gigascience/giw015 28327990 PMC5466708 Matte A Tari LW Delbaere LT How do kinases transfer phosphoryl groups? Structure 1998 6 413 9 10.1016/s0969-2126(98)00043-4 9562560 Krämer J Bar-Or A Turner TJ Wiendl H Bruton tyrosine kinase inhibitors for multiple sclerosis Nat Rev Neurol 2023 19 289 304 10.1038/s41582-023-00800-7 37055617 PMC10100639 Liu DZ Cheng XY Ander BP Xu H Davis RR Gregg JP et al. Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons Neurobiol Dis 2008 30 201 11 10.1016/j.nbd.2008.01.006 18343677 PMC2413433 Liu DZ Ander BP Xu H Shen Y Kaur P Deng W et al. Blood-brain barrier breakdown and repair by Src after thrombin-induced injury Ann Neurol 2010 67 526 33 10.1002/ana.21924 20437588 PMC2919346 Liu DZ Sharp FR Van KC Ander BP Ghiasvand R Zhan X et al. Inhibition of SRC family kinases protects hippocampal neurons and improves cognitive function after traumatic brain injury J Neurotrauma 2014 31 1268 76 10.1089/neu.2013.3250 24428562 PMC4108941 Liu DZ Waldau B Ander BP Zhan X Stamova B Jickling GC et al. Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin J Cereb Blood Flow Metab 2017 37 2359 67 10.1177/0271678X16666291 27624844 PMC5531336 Sharma S Carlson S Gregory-Flores A Hinojo-Perez A Olson A Thippeswamy T Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy Neurobiol Dis 2021 156 105410 10.1016/j.nbd.2021.105410 34087381 PMC8325782 Ye Z Izadi A Gurkoff GG Rickerl K Sharp FR Ander BP et al. Combined Inhibition of Fyn and c-Src Protects Hippocampal Neurons and Improves Spatial Memory via ROCK after Traumatic Brain Injury J Neurotrauma 2022 39 520 9 10.1089/neu.2021.0311 35109711 PMC8978569 Jeon BT Jeong EA Park SY Son H Shin HJ Lee DH et al. The Rho-kinase (ROCK) inhibitor Y-27632 protects against excitotoxicity-induced neuronal death in vivo and in vitro Neurotox Res 2013 23 238 48 10.1007/s12640-012-9339-2 22810835 Kubo T Yamashita T Rho-ROCK inhibitors for the treatment of CNS injury Recent Pat CNS Drug Discov 2007 2 173 9 10.2174/157488907782411738 18221230 Ohnishi M Katsuki H Fujimoto S Takagi M Kume T Akaike A Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury Exp Neurol 2007 206 43 52 10.1016/j.expneurol.2007.03.030 17498698 Di Giovanni S Movsesyan V Ahmed F Cernak I Schinelli S Stoica B et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury Proc Natl Acad Sci U S A 2005 102 8333 8 10.1073/pnas.0500989102 15923260 PMC1149422 Hilton GD Stoica BA Byrnes KR Faden AI Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma J Cereb Blood Flow Metab 2008 28 1845 59 10.1038/jcbfm.2008.75 18612315 PMC2718694 Kabadi SV Stoica BA Hanscom M Loane DJ Kharebava G Murray Ii MG et al. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury Neurotherapeutics 2012 9 405 21 10.1007/s13311-011-0095-4 22167461 PMC3324621 Aubrecht TG Faden AI Sabirzhanov B Glaser EP Roelofs BA Polster BM et al. Comparing effects of CDK inhibition and E2F1/2 ablation on neuronal cell death pathways in vitro and after traumatic brain injury Cell Death Dis 2018 9 1121 10.1038/s41419-018-1156-y 30401820 PMC6219504 Osuga H Osuga S Wang F Fetni R Hogan MJ Slack RS et al. Cyclin-dependent kinases as a therapeutic target for stroke Proc Natl Acad Sci U S A 2000 97 10254 9 10.1073/pnas.170144197 10944192 PMC27851 Iguchi M Honjo J Yamamoto T Kanai K Baricitinib as a treatment for myasthenia gravis: a case report Neuromuscul Disord 2024 41 56 8 10.1016/j.nmd.2024.06.006 38954991 Laursen JC Rotbain Curovic V Kroonen MYAM Jongs N Zobel EH Hansen TW et al. Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial Diabetes Obes Metab 2023 25 3064 7 10.1111/dom.15180 37385968 Gonzales MM Garbarino VR Marques Zilli E Petersen RC Kirkland JL Tchkonia T et al. Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial J Prev Alzheimers Dis 2022 9 22 9 10.14283/jpad.2021.62 35098970 PMC8612719 Gonzales MM Garbarino VR Kautz TF Palavicini JP Lopez-Cruzan M Dehkordi SK et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial Nat Med 2023 29 2481 8 10.1038/s41591-023-02543-w 37162971 PMC10168460 Joussen AM Wolf S Kaiser PK Boyer D Schmelter T Sandbrink R et al. The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial Br J Clin Pharmacol 2019 85 347 55 10.1111/bcp.13794 30341774 PMC6339971 Palma JA Martinez J Millar Vernetti P Ma T Perez MA Zhong J et al. mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis Mov Disord 2022 37 778 89 10.1002/mds.28923 35040506 PMC9018525 Liu Y Huang Z Zhang TX Han B Yang G Jia D et al. Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder J Neuroinflammation 2023 20 309 10.1186/s12974-023-02997-2 38129902 PMC10740299 Specchio N Nabbout R Aronica E Auvin S Benvenuto A de Palma L et al. Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy Eur J Paediatr Neurol 2023 47 25 34 10.1016/j.ejpn.2023.08.005 37669572 Tong J Ji T Liu T Liu J Chen Y Li Z et al. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis Epilepsy Behav 2024 152 109653 10.1016/j.yebeh.2024.109653 38277848 Edmonds B Ngo JP Groves A Reyes B Gott RA Chia DJ et al. Multi-disciplinary team approach for pediatric hemimegalencephaly: Insights from a single institutional case series Epilepsia Open 2024 9 2510 7 10.1002/epi4.13079 39442533 PMC11633684 Pearsson K Björk Werner J Lundgren J Gränse L Karlsson E Källén K et al. Childhood tuberous sclerosis complex in southern Sweden: a paradigm shift in diagnosis and treatment BMC Pediatr 2023 23 329 10.1186/s12887-023-04137-4 37386496 PMC10308728 Leitner DF Kanshin E Askenazi M Siu Y Friedman D Devore S et al. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia PLoS One 2022 17 e0268597 10.1371/journal.pone.0268597 35587487 PMC9119437 Butera S Tavarozzi R Brunello L Rivela P Sofia A Viero L et al. The black swan: a case of central nervous system graft-versus-host disease J Basic Clin Physiol Pharmacol 2023 34 805 809 10.1515/jbcpp-2023-0194 37843253 Castellani F Visentin A Schirinzi E Salvalaggio A Cacciavillani M Candiotto C et al. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets Neurol Neuroimmunol Neuroinflamm 2023 10 e200122 10.1212/NXI.0000000000200122 37137530 PMC10155778 Shirani A Saez-Calveras N Antel JP Yaqubi M Moore W Brewster AL et al. Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy Ther Adv Neurol Disord 2024 17 17562864241276204 10.1177/17562864241276204 39371642 PMC11456174 Li Y Sun Z Zhu H Sun Y Shteyman DB Markx S et al. Inhibition of Abl Kinase by Imatinib Can Rescue the Compromised Barrier Function of 22q11.2DS Patient-iPSC-Derived Blood-Brain Barriers Cells 2023 12 422 10.3390/cells12030422 36766762 PMC9913366 Vos EM Geraedts VJ van der Lugt A Dippel DWJ Wermer MJH Hofmeijer J et al. Systematic Review - Combining Neuroprotection With Reperfusion in Acute Ischemic Stroke Front Neurol 2022 13 840892 10.3389/fneur.2022.840892 35370911 PMC8969766 Frémond ML Hully M Fournier B Barrois R Lévy R Aubart M et al. JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study J Clin Immunol 2023 43 1436 47 10.1007/s10875-023-01500-z 37171742 PMC10175907 Jang Y Lee WJ Lee HS Chu K Lee SK Lee ST Tofacitinib treatment for refractory autoimmune encephalitis Epilepsia 2021 62 e53 9 10.1111/epi.16848 33656171 Wang F Li S Wang TY Lopez GA Antoshechkin I Chou TF P97/VCP ATPase inhibitors can rescue p97 mutation-linked motor neuron degeneration Brain Commun 2022 4 fcac176 10.1093/braincomms/fcac176 35865348 PMC9294923 Wang X Ma L Li J Kong F Activated cell-cycle CDK4/CyclinD1-pRB-E2F1 signaling pathway is involved in the apoptosis of dorsal raphe nucleus in the rat model of PTSD Biochem Biophys Res Commun 2022 602 142 8 10.1016/j.bbrc.2022.02.108 35272144 Liu T Hou K Li J Han T Liu S Wei J Alzheimer’s Disease and Aging Association: Identification and Validation of Related Genes J Prev Alzheimers Dis 2024 11 196 213 10.14283/jpad.2023.101 38230733 Lee HJ Hoe HS Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signaling Pharmacol Res 2023 190 106725 10.1016/j.phrs.2023.106725 36907286 Li T Li L Peng R Hao H Zhang H Gao Y et al. Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway Cells 2022 11 3588 10.3390/cells11223588 36429017 PMC9688110 Chen YJ Hsu CC Shiao YJ Wang HT Lo YL Lin AMY Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation Sci Rep 2019 9 2516 10.1038/s41598-019-38676-7 30792526 PMC6385176 Linnerbauer M Lößlein L Vandrey O Tsaktanis T Beer A Naumann UJ et al. Intranasal delivery of a small-molecule ErbB inhibitor promotes recovery from acute and late-stage CNS inflammation JCI Insight 2022 7 e154824 10.1172/jci.insight.154824 35393953 PMC9057609 Schachenhofer J Gruber VE Fehrer SV Haider C Glatter S Liszewska E et al. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex? Neuropathol Appl Neurobiol 2024 50 e12974 10.1111/nan.12974 38562027 Gómez-Oliva R Geribaldi-Doldán N Domínguez-García S Pardillo-Díaz R Martínez-Ortega S Oliva-Montero JM et al. Targeting epidermal growth factor receptor to recruit newly generated neuroblasts in cortical brain injuries J Transl Med 2023 21 867 10.1186/s12967-023-04707-1 38037126 PMC10687845 Singh CSB Choi KB Munro L Wang HY Pfeifer CG Jefferies WA Reversing pathology in a preclinical model of Alzheimer’s disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics EBioMedicine 2021 71 103503 10.1016/j.ebiom.2021.103503 34534764 PMC8449085 Wang S Guo Y Cao RQ Zhu YM Qiao SG Du HP et al. VEGFD/VEGFR3 signaling contributes to the dysfunction of the astrocyte IL-3/microglia IL-3Rα cross-talk and drives neuroinflammation in mouse ischemic stroke Acta Pharmacol Sin 2025 46 292 307 10.1038/s41401-024-01405-6 39478160 Wang K Zhou W Wen L Jin X Meng T Li S et al. The protective effects of Axitinib on blood-brain barrier dysfunction and ischemia-reperfusion injury in acute ischemic stroke Exp Neurol 2024 379 114870 10.1016/j.expneurol.2024.114870 38897539 Königs V Pierre S Schicht M Welss J Hahnefeld L Rimola V et al. GPR40 Activation Abolishes Diabetes-Induced Painful Neuropathy by Suppressing VEGF-A Expression Diabetes 2022 71 774 87 10.2337/db21-0711 35061031 Dutton JW 3rd, Chen H, You C, Brodie MS, Lasek AW. Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area Addict Biol 2017 22 665 78 10.1111/adb.12358 26752591 PMC4940304 Hamada K Ferguson LB Mayfield RD Krishnan HR Maienschein-Cline M Lasek AW Binge-like ethanol drinking activates anaplastic lymphoma kinase signaling and increases the expression of STAT3 target genes in the mouse hippocampus and prefrontal cortex Genes Brain Behav 2021 e12729 10.1111/gbb.12729 33641239 PMC8944393 Hu Y Chang L Zhu Y Geng X Liu Z Wang R et al. Inhibition of Anaplastic Lymphoma Kinase Protects From Ischemic Stroke Stroke 2024 55 1075 85 10.1161/STROKEAHA.123.045991 38445502 Gavegnano C Haile WB Hurwitz S Tao S Jiang Y Schinazi RF et al. Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro J Neuroinflammation 2019 16 182 10.1186/s12974-019-1565-6 31561750 PMC6764124 Nakamura J Yanagida M Saito K Kamata Y Nagashima T Iwamoto M et al. Epstein-Barr virus encephalitis in a patient with rheumatoid arthritis Mod Rheumatol Case Rep 2022 6 160 2 10.1093/mrcr/rxab045 34971371 Dang C Lu Y Chen X Li Q Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway Front Immunol 2021 12 650708 10.3389/fimmu.2021.650708 33927721 PMC8076548 Tuttle KD Waugh KA Araya P Minter R Orlicky DJ Ludwig M et al. JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome Cell Rep 2020 33 108407 10.1016/j.celrep.2020.108407 33207208 PMC7727402 Zheng XQ Huang JF Lin JL Zhu YX Wang MQ Guo ML et al. Controlled release of baricitinib from a thermos-responsive hydrogel system inhibits inflammation by suppressing JAK2/STAT3 pathway in acute spinal cord injury Colloids Surf B Biointerfaces 2021 199 111532 10.1016/j.colsurfb.2020.111532 33385822 Liu C Arnold R Henriques G Djabali K Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells Cells 2019 8 1276 10.3390/cells8101276 31635416 PMC6829898 Agarwal K Katare DP Jakhmola-Mani R Foresee Novel Targets for Alzheimer’s Disease by Investigating Repurposed Drugs CNS Neurol Disord Drug Targets 2023 22 1209 31 10.2174/1871527321666220622162622 35733313 König LE Rodriguez S Hug C Daneshvari S Chung A Bradshaw GA et al. TYK2 as a novel therapeutic target in Alzheimer’s Disease with TDP-43 inclusions BioRxiv 595773 [Preprint]. 2024 [cited 2025 May 26]. Available from: https://www.biorxiv.org/content/10.1101/2024.06.04.595773v1 Hindam MO Ahmed LA El Sayed NS Khattab M Sallam NA Repositioning of baricitinib for management of memory impairment in ovariectomized/D-galactose treated rats: A potential role of JAK2/STAT3-PI3K/AKT/mTOR signaling pathway Life Sci 2024 351 122838 10.1016/j.lfs.2024.122838 38897347 Bernal-Bermúdez B Martínez-López A Martínez-Morcillo FJ Tyrkalska SD Martínez-Menchón T Mesa-Del-Castillo P et al. A zebrafish model of Ifih1-driven Aicardi-Goutières syndrome reproduces the interferon signature and the exacerbated inflammation of patients Front Immunol 2023 14 1294766 10.3389/fimmu.2023.1294766 38077314 PMC10704509 Železnik M Soltirovska Šalamon A Debeljak M Goropevšek A Šuštar N Ključevšek D et al. Case report: Pneumocystis jirovecii pneumonia in a severe case of Aicardi-Goutières syndrome with an IFIH1 gain-of-function mutation mimicking combined immunodeficiency Front Immunol 2023 13 1033513 10.3389/fimmu.2022.1033513 36685504 PMC9846174 Jafarpour S Suddock J Hawes D Santoro JD Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome J Clin Immunol 2024 44 68 10.1007/s10875-024-01672-2 38381212 Ryckmans C Donge M Marchèse A Mastouri M Thomee C Stouffs K et al. TREX-1 related Aicardi-Goutières syndrome improved by Janus kinase inhibitor Am J Med Genet A 2024 194 e63510 10.1002/ajmg.a.63510 38135344 Richardson PJ Smith DP de Giorgio A Snetkov X Almond-Thynne J Cronin S et al. Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis Transl Neurodegener 2023 12 47 10.1186/s40035-023-00380-y 37828541 PMC10568794 Makabe K Okada H Tachibana N Ishikura H Ito N Tanaka M et al. Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons Arthritis Res Ther 2024 26 121 10.1186/s13075-024-03354-1 38879555 PMC11179219 Acosta-González RI Hernández-Jiménez AY Ramírez-Quintanilla LY Torres-Rodríguez HF Vargas Muñoz VM Jiménez-Andrade JM Effect of 28 days treatment of baricitinib on mechanical allodynia, osteopenia, and loss of nerve fibers in an experimental model of type-1 diabetes mellitus Pharmacol Rep 2024 76 1079 88 10.1007/s43440-024-00634-0 39155357 Wohlrab J Stintzing D Schultz L Jügelt K Schroeder OH Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch Skin Pharmacol Physiol 2022 35 94 101 10.1159/000519669 34530431 PMC8985001 Schapansky J Grinberg YY Osiecki DM Freeman EA Walker SG Karran E et al. MEK1/2 activity modulates TREM2 cell surface recruitment J Biol Chem 2021 296 100218 10.1074/jbc.RA120.014352 33839686 PMC7948395 Ma L Manaenko A Ou YB Shao AW Yang SX Zhang JH Bosutinib Attenuates Inflammation via Inhibiting Salt-Inducible Kinases in Experimental Model of Intracerebral Hemorrhage on Mice Stroke 2017 48 3108 16 10.1161/STROKEAHA.117.017681 29018127 PMC5679716 Liang S Pong K Gonzales C Chen Y Ling HP Mark RJ et al. Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia J Pharmacol Exp Ther 2009 331 827 35 10.1124/jpet.109.156562 19741150 Hebron ML Javidnia M Moussa CE Tau clearance improves astrocytic function and brain glutamate-glutamine cycle J Neurol Sci 2018 391 90 9 10.1016/j.jns.2018.06.005 30103978 Hebron ML Lonskaya I Olopade P Selby ST Pagan F Moussa CE Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy J Clin Cell Immunol 2014 5 259 10.4172/2155-9899.1000259 25635231 PMC4308054 Wenqiang C Lonskaya I Hebron ML Ibrahim Z Olszewski RT Neale JH et al. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice Hum Mol Genet 2014 23 4960 9 10.1093/hmg/ddu211 24847002 Lonskaya I Hebron ML Desforges NM Franjie A Moussa CE Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance EMBO Mol Med 2013 5 1247 62 10.1002/emmm.201302771 23737459 PMC3944464 Lonskaya I Hebron ML Selby ST Turner RS Moussa CE Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models Neuroscience 2015 304 316 27 10.1016/j.neuroscience.2015.07.070 26235435 Heyburn L Hebron ML Smith J Winston C Bechara J Li Z et al. Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis J Neurochem 2016 139 610 23 10.1111/jnc.13763 27507246 Yilmaz S Alkan T Ballar Kirmizibayrak P A new underlying mechanism for the neuroprotective effect of bosutinib: Reverting toxicity-induced PARylation in SIN1-mediated neurotoxicity J Biochem Mol Toxicol 2021 35 e22915 10.1002/jbt.22915 34519134 Kiris E Burnett JC Nuss JE Wanner LM Peyser BD Du HT et al. SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons Neurotox Res 2015 27 384 98 10.1007/s12640-015-9526-z 25782580 PMC4455898 Khan SA Khan S Kausar H Shah R Luitel A Gautam S et al. Insights into the management of Lewy body dementia: a scoping review Ann Med Surg (Lond) 2024 86 930 42 10.1097/MS9.0000000000001664 38333295 PMC10849442 Skylar-Scott IA Sha SJ Lewy Body Dementia: An Overview of Promising Therapeutics Curr Neurol Neurosci Rep 2023 23 581 92 10.1007/s11910-023-01292-0 37572228 Ito D Morimoto S Takahashi S Okada K Nakahara J Okano H Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis Brain 2023 146 13 9 10.1093/brain/awac306 36004509 Noguchi Y Asano H Masuda R Teshigawara Y Go M Kimura M et al. Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study Oncology 2024 102 996 1003 10.1159/000539426 38768582 Imamura K Izumi Y Nagai M Nishiyama K Watanabe Y Hanajima R et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial EClinicalMedicine 2022 53 101707 10.1016/j.eclinm.2022.101707 36467452 PMC9716331 Tang X Drotar J Li K Clairmont CD Brumm AS Sullins AJ et al. Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice Sci Transl Med 2019 11 eaau0164 10.1126/scitranslmed.aau0164 31366578 PMC8140401 Tucker Edmister S Del Rosario Hernández T Ibrahim R Brown CA Gore SV Kakodkar R et al. Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles Sci Rep 2022 12 6120 10.1038/s41598-022-10133-y 35449173 PMC9023506 Lee HJ Hwang JW Park JH Jeong YJ Jang JY Hoe HS Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD Mol Brain 2023 16 63 10.1186/s13041-023-01051-9 37580778 PMC10426186 Del Rosario Hernandez T Joshi NR Gore SV Kreiling JA Creton R Combining supervised and unsupervised analyses to quantify behavioral phenotypes and validate therapeutic efficacy in a triple transgenic mouse model of Alzheimer’s disease Biomed Pharmacother 2024 181 117718 10.1016/j.biopha.2024.117718 39637754 PMC11755788 Bolz SN Salentin S Jennings G Haupt VJ Sterneckert J Schroeder M Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor Comput Struct Biotechnol J 2021 19 3674 81 10.1016/j.csbj.2021.06.013 34285770 PMC8258795 Lim JW Kim SK Choi SY Kim DH Gadhe CG Lee HN et al. Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer’s disease Eur J Med Chem 2018 157 405 22 10.1016/j.ejmech.2018.07.071 30103190 Defaye M Iftinca MC Gadotti VM Basso L Abdullah NS Cuménal M et al. The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain J Clin Invest 2022 132 e154317 10.1172/JCI154317 35608912 PMC9197515 Yang Z Ahn HJ Nam HW Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells Korean J Parasitol 2014 52 439 41 10.3347/kjp.2014.52.4.439 25246725 PMC4170042 Camp E Anderson PJ Zannettino ACW Glackin CA Gronthos S Tyrosine kinase receptor c-ros-oncogene 1 inhibition alleviates aberrant bone formation of TWIST-1 haploinsufficient calvarial cells from Saethre-Chotzen syndrome patients J Cell Physiol 2018 233 7320 32 10.1002/jcp.26563 29663378 Cruz SA Qin Z Stewart AFR Chen HH Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury Neural Regen Res 2018 13 252 6 10.4103/1673-5374.226394 29557374 PMC5879896 Sugaya T Kanno H Matsuda M Handa K Tateda S Murakami T et al. B-RAFV600E Inhibitor Dabrafenib Attenuates RIPK3-Mediated Necroptosis and Promotes Functional Recovery after Spinal Cord Injury Cells 2019 8 1582 10.3390/cells8121582 31817643 PMC6953123 Uenaka T Satake W Cha PC Hayakawa H Baba K Jiang S et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson’s disease Hum Mol Genet 2018 27 3974 85 10.1093/hmg/ddy279 30137437 PMC6216208 Okamoto T Parkinson’s Disease: amantadine, zonisamide, dabrafenib Brain Nerve 2019 71 953 9. Japanese 10.11477/mf.1416201387 31506397 Elkouzi A Rauschkolb P Grogg KL Gilchrist JM Neurohistiocytosis of the Cerebellum: A Rare Cause of Ataxia Mov Disord Clin Pract 2015 3 125 9 10.1002/mdc3.12277 30363424 PMC6178653 Tu T Yu J Jiang C Zhang S Li J Ren J et al. Somatic BrafV600E mutation in the cerebral endothelium induces brain arteriovenous malformations Angiogenesis 2024 27 441 60 10.1007/s10456-024-09918-8 38700584 Saminathan H Charli A Luo J Panicker N Gordon R Hostetter JM et al. Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research Eur J Pharmacol 2020 881 173259 10.1016/j.ejphar.2020.173259 32565338 PMC7483871 Gangoso E Talaverón R Jaraíz-Rodríguez M Domínguez-Prieto M Ezan P Koulakoff A et al. A c-Src Inhibitor Peptide Based on Connexin43 Exerts Neuroprotective Effects through the Inhibition of Glial Hemichannel Activity Front Mol Neurosci 2017 10 418 10.3389/fnmol.2017.00418 29326548 PMC5737028 El-Nimri NW Moore SM Zangwill LM Proudfoot JA Weinreb RN Skowronska-Krawczyk D et al. Evaluating the neuroprotective impact of senolytic drugs on human vision Sci Rep 2020 10 21752 10.1038/s41598-020-78802-4 33303874 PMC7730173 Musi N Valentine JM Sickora KR Baeuerle E Thompson CS Shen Q et al. Tau protein aggregation is associated with cellular senescence in the brain Aging Cell 2018 17 e12840 10.1111/acel.12840 30126037 PMC6260915 Azizi G Goudarzvand M Afraei S Sedaghat R Mirshafiey A Therapeutic effects of dasatinib in mouse model of multiple sclerosis Immunopharmacol Immunotoxicol 2015 37 287 94 10.3109/08923973.2015.1028074 25975582 Katsumata R Ishigaki S Katsuno M Kawai K Sone J Huang Z et al. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis PLoS One 2012 7 e46185 10.1371/journal.pone.0046185 23049975 PMC3458026 Lawana V Singh N Sarkar S Charli A Jin H Anantharam V et al. Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System J Neuroimmune Pharmacol 2017 12 624 60 10.1007/s11481-017-9746-5 28466394 PMC5668207 Torres P Anerillas C Ramírez-Núñez O Fernàndez A Encinas M Povedano M et al. A motor neuron disease mouse model reveals a non-canonical profile of senescence biomarkers Dis Model Mech 2022 15 dmm049059 10.1242/dmm.049059 35916061 PMC9459393 Fang Y Medina D Stockwell R McFadden S Quinn K Peck MR et al. Sexual dimorphic metabolic and cognitive responses of C57BL/6 mice to Fisetin or Dasatinib and quercetin cocktail oral treatment Geroscience 2023 45 2835 50 10.1007/s11357-023-00843-0 37296266 PMC10643448 Budamagunta V Kumar A Rani A Bean L Manohar-Sindhu S Yang Y et al. Effect of peripheral cellular senescence on brain aging and cognitive decline Aging Cell 2023 22 e13817 10.1111/acel.13817 36959691 PMC10186609 Ogrodnik M Zhu Y Langhi LGP Tchkonia T Krüger P Fielder E et al. Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis Cell Metab 2019 29 1061 77 10.1016/j.cmet.2018.12.008 30612898 PMC6509403 Lin YF Wang LY Chen CS Li CC Hsiao YH Cellular senescence as a driver of cognitive decline triggered by chronic unpredictable stress Neurobiol Stress 2021 15 100341 10.1016/j.ynstr.2021.100341 34095365 PMC8163993 Wang D Howell BW Olson EC Maternal Ethanol Exposure Acutely Elevates Src Family Kinase Activity in the Fetal Cortex Mol Neurobiol 2021 58 5210 23 10.1007/s12035-021-02467-x 34272687 PMC8497457 Cuní-López C Stewart R Oikari LE Nguyen TH Roberts TL Sun Y et al. Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer’s disease J Neuroinflammation 2024 21 50 10.1186/s12974-024-03037-3 38365833 PMC10870454 Mohammad AR Hassan ES Majeed SA PI3K/AKT and STAT3 pathways mediate the neuroprotective effect of dasatinib from acute cerebral injury in endotoxemic mice Res Pharm Sci 2024 19 64 72 10.4103/1735-5362.394821 39006974 PMC11244703 Zhang X Guo J Liu J Liu J Li Z Chen J et al. Exosomal Src from hypoxic vascular smooth muscle cells exacerbates ischemic brain injury by promoting M1 microglial polarization Neurochem Int 2024 179 105819 10.1016/j.neuint.2024.105819 39084350 Yao M Wei Z Nielsen JS Ouyang Y Kakazu A Wang H et al. Senolytic therapy preserves blood-brain barrier integrity and promotes microglia homeostasis in a tauopathy model Neurobiol Dis 2024 202 106711 10.1016/j.nbd.2024.106711 39437971 PMC11600427 Ribierre T Bacq A Donneger F Doladilhe M Maletic M Roussel D et al. Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy Nat Neurosci 2024 27 1125 36 10.1038/s41593-024-01634-2 38710875 PMC11156583 Khan T Hussain AI Casilli TP Frayser L Cho M Williams G et al. Prophylactic senolytic treatment in aged mice reduces seizure severity and improves survival from Status Epilepticus Aging Cell 2024 23 e14239 10.1111/acel.14239 39031751 PMC11488304 Wang C Kang Y Liu P Liu W Chen W Hayashi T et al. Combined use of dasatinib and quercetin alleviates overtraining-induced deficits in learning and memory through eliminating senescent cells and reducing apoptotic cells in rat hippocampus Behav Brain Res 2023 440 114260 10.1016/j.bbr.2022.114260 36535433 Lin X Zhang K Li C Liu K Sun Y Wu W et al. Combination of Dasatinib and Quercetin alleviates heat stress-induced cognitive deficits in aged and young adult male mice Eur J Pharmacol 2024 974 176631 10.1016/j.ejphar.2024.176631 38692425 Wang J Lu Y Carr C Dhandapani KM Brann DW Senolytic therapy is neuroprotective and improves functional outcome long-term after traumatic brain injury in mice Front Neurosci 2023 17 1227705 10.3389/fnins.2023.1227705 37575310 PMC10416099 Orr ME A Need for Refined Senescence Biomarkers and Measures of Senolytics in the Brain J Alzheimers Dis 2024 98 411 5 10.3233/JAD-231462 38461508 PMC11063734 Fang Y Peck MR Quinn K Chapman JE Medina D McFadden SA et al. Senolytic intervention improves cognition, metabolism, and adiposity in female APPNL-F/NL-F mice Geroscience 2025 47 1123 38 10.1007/s11357-024-01308-8 39120687 PMC11872876 Riordan R Rong W Yu Z Ross G Valerio J Dimas-Muñoz J et al. Effect of Nrf2 loss on senescence and cognition of tau-based P301S mice Geroscience 2023 45 1451 69 10.1007/s11357-023-00760-2 36976489 PMC10400516 Ng PY Zhang C Li H Baker DJ Senescence Targeting Methods Impact Alzheimer’s Disease Features in 3xTg Mice J Alzheimers Dis 2024 97 1751 63 10.3233/JAD-230465 38306030 PMC10939718 Krzystyniak A Wesierska M Petrazzo G Gadecka A Dudkowska M Bielak-Zmijewska A et al. Combination of dasatinib and quercetin improves cognitive abilities in aged male Wistar rats, alleviates inflammation and changes hippocampal synaptic plasticity and histone H3 methylation profile Aging (Albany NY) 2022 14 572 95 10.18632/aging.203835 35042834 PMC8833137 Van Houcke J Mariën V Zandecki C Ayana R Pepermans E Boonen K et al. A short dasatinib and quercetin treatment is sufficient to reinstate potent adult neuroregenesis in the aged killifish NPJ Regen Med 2023 8 31 10.1038/s41536-023-00304-4 37328477 PMC10275874 Riessland M Ximerakis M Jarjour AA Zhang B Orr ME Therapeutic targeting of senescent cells in the CNS Nat Rev Drug Discov 2024 23 817 37 10.1038/s41573-024-01033-z 39349637 PMC11927922 Ya J Bayraktutan U Senolytics and Senomorphics Targeting p38MAPK/NF-κB Pathway Protect Endothelial Cells from Oxidative Stress-Mediated Premature Senescence Cells 2024 13 1292 10.3390/cells13151292 39120322 PMC11311971 Ya J Kadir RRA Bayraktutan U Delay of endothelial cell senescence protects cerebral barrier against age-related dysfunction: role of senolytics and senomorphics Tissue Barriers 2023 11 2103353 10.1080/21688370.2022.2103353 35880392 PMC10364655 Ota H Kodama A Dasatinib plus quercetin attenuates some frailty characteristics in SAMP10 mice Sci Rep 2022 12 2425 10.1038/s41598-022-06448-5 35165353 PMC8844286 Faria OW de Aguiar MSS de Mello JE Alvez FL Luduvico KP Garcia DN et al. Senolytics prevent age-associated changes in female mice brain Neurosci Lett 2024 826 137730 10.1016/j.neulet.2024.137730 38485080 Johnson B Cheng L Koenitzer J Catlett IM Schafer P Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways Front Immunol 2024 15 1437512 10.3389/fimmu.2024.1437512 39403378 PMC11472182 Adamek P Heles M Bhattacharyya A Pontearso M Slepicka J Palecek J Dual PI3Kδ/γ Inhibitor Duvelisib Prevents Development of Neuropathic Pain in Model of Paclitaxel-Induced Peripheral Neuropathy J Neurosci 2022 42 1864 81 10.1523/JNEUROSCI.1324-21.2021 35042769 PMC8896539 Koprivica V Cho KS Park JB Yiu G Atwal J Gore B et al. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans Science 2005 310 106 10 10.1126/science.1115462 16210539 Luo Y Tang H Zhang Z Zhao R Wang C Hou W et al. Pharmacological inhibition of epidermal growth factor receptor attenuates intracranial aneurysm formation by modulating the phenotype of vascular smooth muscle cells CNS Neurosci Ther 2022 28 64 76 10.1111/cns.13735 34729926 PMC8673708 Le Pichon CE Dominguez SL Solanoy H Ngu H Lewin-Koh N Chen M et al. EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS PLoS One 2013 8 e62342 10.1371/journal.pone.0062342 23638043 PMC3637182 Pan P Dobrowsky RT Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy Acta Neuropathol Commun 2013 1 39 10.1186/2051-5960-1-39 24252174 PMC3893607 McGuire JF Rouen S Siegfreid E Wright DE Dobrowsky RT Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy Diabetes 2009 58 2677 86 10.2337/db09-0594 19675140 PMC2768162 Wang L Chiang HC Wu W Liang B Xie Z Yao X et al. Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss Proc Natl Acad Sci U S A 2012 109 16743 8 10.1073/pnas.1208011109 23019586 PMC3478595 Lechpammer M Tran YP Wintermark P Martínez-Cerdeño V Krishnan VV Ahmed W et al. Upregulation of cystathionine β-synthase and p70S6K/S6 in neonatal hypoxic ischemic brain injury Brain Pathol 2017 27 449 58 10.1111/bpa.12421 27465493 PMC8028969 Kurdi A Roth L Van der Veken B Van Dam D De Deyn PP De Doncker M et al. Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis Vascul Pharmacol 2019 113 70 6 10.1016/j.vph.2018.12.004 30590134 Li D Wang C Yao Y Chen L Liu G Zhang R et al. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type FASEB J 2016 30 3388 99 10.1096/fj.201600495R 27342766 Suvanish Kumar VS Pretorius E Rajanikant GK The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro Cell Mol Neurobiol 2018 38 1383 97 10.1007/s10571-018-0605-6 30062636 PMC11481845 Forouzanfar F Ebrahimi PR Sadeghnia HR Neuroprotection of Everolimus Against Focal Cerebral Ischemia-Reperfusion Injury in Rats J Stroke Cerebrovasc Dis 2022 31 106576 10.1016/j.jstrokecerebrovasdis.2022.106576 35633587 Cassano T Magini A Giovagnoli S Polchi A Calcagnini S Pace L et al. Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer’s disease Exp Neurol 2019 311 88 105 10.1016/j.expneurol.2018.09.011 30243986 Fanoudi S Hosseini M Alavi MS Boroushaki MT Hosseini A Sadeghnia HR Everolimus, a mammalian target of rapamycin inhibitor, ameliorated streptozotocin-induced learning and memory deficits via neurochemical alterations in male rats EXCLI J 2018 17 999 1017 10.17179/excli2018-1626 30564080 PMC6295637 Roscic A Baldo B Crochemore C Marcellin D Paganetti P Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model J Neurochem 2011 119 398 407 10.1111/j.1471-4159.2011.07435.x 21854390 Fox JH Connor T Chopra V Dorsey K Kama JA Bleckmann D et al. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington’s disease Mol Neurodegener 2010 5 26 10.1186/1750-1326-5-26 20569486 PMC2908080 Chen L Zhang Y Li D Zhang N Liu R Han B et al. Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway J Neuroimmunol 2016 299 164 71 10.1016/j.jneuroim.2016.09.008 27725116 Dello Russo C Lisi L Tringali G Navarra P Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation Biochem Pharmacol 2009 78 1242 51 10.1016/j.bcp.2009.06.097 19576187 Bansal S Agrawal M Mahendiratta S Kumar S Arora S Joshi R et al. Everolimus: A potential therapeutic agent targeting PI3K/Akt pathway in brain insulin system dysfunction and associated neurobehavioral deficits Fundam Clin Pharmacol 2021 35 1018 31 10.1111/fcp.12677 33783880 Alavi MS Fanoudi S Hosseini A Jalili-Nik M Bagheri A Sadeghnia HR Everolimus attenuates glutamate-induced PC12 cells death Int J Neurosci 2023 133 457 66 10.1080/00207454.2021.1929210 33998365 Han R Gao J Zhai H Xiao J Ding Y Hao J RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages Exp Neurol 2016 280 106 14 10.1016/j.expneurol.2016.04.005 27063582 Hoepner R Bagnoud M Pistor M Salmen A Briner M Synn H et al. Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis Acta Neuropathol 2019 138 443 56 10.1007/s00401-019-02018-8 31030237 PMC6689294 Schneider M de Vries PJ Schönig K Rößner V Waltereit R mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus Eur Arch Psychiatry Clin Neurosci 2017 267 455 63 10.1007/s00406-016-0703-8 27263037 Petrasek T Vojtechova I Klovrza O Tuckova K Vejmola C Rak J et al. mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus J Neurodev Disord 2021 13 14 10.1186/s11689-021-09357-2 33863288 PMC8052752 Mishra N Wang P Goldsmith D Zhao X Xue Y Christians U et al. Everolimus does not prevent Lafora body formation in murine Lafora disease Neurol Genet 2017 3 e127 10.1212/NXG.0000000000000127 28097224 PMC5224705 Nguyen LH Leiser SC Song D Brunner D Roberds SL Wong M et al. Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex Epilepsy Res 2022 181 106890 10.1016/j.eplepsyres.2022.106890 35219048 PMC8930622 Aronica E Specchio N Luinenburg MJ Curatolo P Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy Brain 2023 146 2694 710 10.1093/brain/awad048 36806388 PMC10316778 Zhao W Xie C Zhang X Liu J Liu J Xia Z Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy Brain Behav 2023 13 e2995 10.1002/brb3.2995 37221133 PMC10275542 Bonazzi S Gray A Thomsen NM Biag J Labbe-Giguere N Keaney EP et al. Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes J Med Chem 2023 66 9095 119 10.1021/acs.jmedchem.3c00705 37399505 Shirzad S Vafaee F Forouzanfar F The Neuroprotective Effects and Probable Mechanisms of Everolimus in a Rat Model of Intracerebral Hemorrhage Cell Mol Neurobiol 2023 43 4219 30 10.1007/s10571-023-01409-6 37747596 PMC11407710 Qiu X Zhou R Su X Ying J Qu Y Mu D Pleiotrophin ameliorates white matter injury of neonatal rats by activating the mTOR/YY1/Id4 signaling pathway FASEB J 2023 37 e23082 10.1096/fj.202201766RRR 37462506 Tsai CW Ho SY Chen IC Chang KC Chen HJ Tsai FC et al. Abnormal increased mTOR signaling regulates seizure threshold in Dravet syndrome Neuropharmacology 2025 262 110166 10.1016/j.neuropharm.2024.110166 39374769 Huang XY Hu QP Shi HY Zheng YY Hu RR Guo Q Everolimus inhibits PI3K/Akt/mTOR and NF-kB/IL-6 signaling and protects seizure-induced brain injury in rats J Chem Neuroanat 2021 114 101960 10.1016/j.jchemneu.2021.101960 33915267 Yang MT Lin YC Ho WH Liu CL Lee WT Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures J Neuroinflammation 2017 14 15 10.1186/s12974-017-0797-6 28109197 PMC5251325 Tao P Jing Z Shou-Hong G Shu-Juan P Jian-Peng J Wen-Quan L et al. Effects of leptin on norepinephrine in acute ischemic stroke Pharmazie 2019 74 477 80 10.1691/ph.2019.9379 31526440 Yue X Liu L Yan H Gui Y Zhao J Zhang P Intracerebral Hemorrhage Induced Brain Injury Is Mediated by the Interleukin-12 Receptor in Rats Neuropsychiatr Dis Treat 2020 16 891 900 10.2147/NDT.S228773 32308392 PMC7142330 Zhang Q Zhang Y Diamond S Boer J Harris JJ Li Y et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke’s encephalopathy Drug Metab Dispos 2014 42 1656 62 10.1124/dmd.114.058883 25063672 Hazell AS Afadlal S Cheresh DA Azar A Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy Neurosci Lett 2017 642 163 7 10.1016/j.neulet.2017.01.041 28109775 Zhou Y Li C Li D Zheng Y Wang J IL-5 blocks apoptosis and tau hyperphosphorylation induced by Aβ25-35 peptide in PC12 cells J Physiol Biochem 2017 73 259 66 10.1007/s13105-017-0550-8 28132394 Feng Y Shen J He J Lu M Schizophrenia and cell senescence candidate genes screening, machine learning, diagnostic models, and drug prediction Front Psychiatry 2023 14 1105987 10.3389/fpsyt.2023.1105987 37113536 PMC10126505 Duan QQ Wang H Su WM Gu XJ Shen XF Jiang Z et al. TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro BMC Med 2024 22 96 10.1186/s12916-024-03314-1 38443977 PMC10916235 Zhou G Xiang T Xu Y He B Wu L Zhu G et al. Fruquintinib/HMPL-013 ameliorates cognitive impairments and pathology in a mouse model of cerebral amyloid angiopathy (CAA) Eur J Pharmacol 2023 939 175446 10.1016/j.ejphar.2022.175446 36470443 Xue W Zhao Y Xiao Z Wu X Ma D Han J et al. Epidermal growth factor receptor-extracellular-regulated kinase blockade upregulates TRIM32 signaling cascade and promotes neurogenesis after spinal cord injury Stem Cells 2020 38 118 33 10.1002/stem.3097 31621984 Mizuno M Sotoyama H Namba H Shibuya M Eda T Wang R et al. ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions Transl Psychiatry 2013 3 e252 10.1038/tp.2013.29 23632456 PMC3641415 Zheng Y Shang F An L Zhao H Liu X NOD2-RIP2 contributes to the inflammatory responses of mice in vivo to Streptococcus pneumoniae Neurosci Lett 2018 671 43 9 10.1016/j.neulet.2018.01.057 29408491 Lopez Corcino Y Gonzalez Ferrer S Mantilla LE Trikeriotis S Yu JS Kim S et al. Toxoplasma gondii induces prolonged host epidermal growth factor receptor signalling to prevent parasite elimination by autophagy: Perspectives for in vivo control of the parasite Cell Microbiol 2019 21 e13084 10.1111/cmi.13084 31290228 PMC6771541 Li D Lian L Huang L Gamdzyk M Huang Y Doycheva D et al. Delayed recanalization reduced neuronal apoptosis and neurological deficits by enhancing liver-derived trefoil factor 3-mediated neuroprotection via LINGO2/EGFR/Src signaling pathway after middle cerebral artery occlusion in rats Exp Neurol 2024 371 114607 10.1016/j.expneurol.2023.114607 37935323 PMC11585322 Dhamodharan J Sekhar G Muthuraman A Epidermal Growth Factor Receptor Kinase Inhibitor Ameliorates β-Amyloid Oligomer-Induced Alzheimer Disease in Swiss Albino Mice Molecules 2022 27 5182 10.3390/molecules27165182 36014421 PMC9412386 Pastor-Alonso O Durá I Bernardo-Castro S Varea E Muro-García T Martín-Suárez S et al. HB-EGF activates EGFR to induce reactive neural stem cells in the mouse hippocampus after seizures Life Sci Alliance 2024 7 e202201840 10.26508/lsa.202201840 38977310 PMC11231495 Ito M Shichita T Okada M Komine R Noguchi Y Yoshimura A et al. Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury Nat Commun 2015 6 7360 10.1038/ncomms8360 26059659 PMC4490404 Jin L Mo Y Yue EL Liu Y Liu KY Ibrutinib ameliorates cerebral ischemia/reperfusion injury through autophagy activation and PI3K/Akt/mTOR signaling pathway in diabetic mice Bioengineered 2021 12 7432 45 10.1080/21655979.2021.1974810 34605340 PMC8806753 Yu CG Bondada V Iqbal H Moore KL Gensel JC Bondada S et al. Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury Int J Mol Sci 2021 23 355 10.3390/ijms23010355 35008785 PMC8745213 Torabi S Anjamrooz SH Zeraatpisheh Z Aligholi H Azari H Ibrutinib reduces neutrophil infiltration, preserves neural tissue and enhances locomotor recovery in mouse contusion model of spinal cord injury Anat Cell Biol 2021 54 350 60 10.5115/acb.20.299 34031271 PMC8493027 Ekpenyong-Akiba AE Poblocka M Althubiti M Rada M Jurk D Germano S et al. Amelioration of age-related brain function decline by Bruton’s tyrosine kinase inhibition Aging Cell 2020 19 e13079 10.1111/acel.13079 31736210 PMC6974713 Lee HJ Jeon SG Kim J Kang RJ Kim SM Han KM et al. Ibrutinib modulates Aβ/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer’s disease Aging Cell 2021 20 e13332 10.1111/acel.13332 33709472 PMC7963331 Keaney J Gasser J Gillet G Scholz D Kadiu I Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease J Neuroimmune Pharmacol 2019 14 448 61 10.1007/s11481-019-09839-0 30758770 PMC6707957 Nam HY Nam JH Yoon G Lee JY Nam Y Kang HJ et al. Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice J Neuroinflammation 2018 15 271 10.1186/s12974-018-1308-0 30231870 PMC6145206 Ghosh S Mohammed Z Singh I Bruton’s tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress J Neuroinflammation 2021 18 289 10.1186/s12974-021-02322-9 34895246 PMC8665324 Li W Ali T He K Liu Z Shah FA Ren Q et al. Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression Brain Behav Immun 2021 92 10 24 10.1016/j.bbi.2020.11.008 33181270 Zheng M Li K Chen T Liu S He L Geniposide protects depression through BTK/JAK2/STAT1 signaling pathway in lipopolysaccharide-induced depressive mice Brain Res Bull 2021 170 65 73 10.1016/j.brainresbull.2021.02.008 33561536 Huggett SB Hatfield JS Walters JD McGeary JE Welsh JW Mackay TFC et al. Ibrutinib as a potential therapeutic for cocaine use disorder Transl Psychiatry 2021 11 623 10.1038/s41398-021-01737-5 34880215 PMC8654982 Liu C Yao K Tian Q Guo Y Wang G He P et al. CXCR4-BTK axis mediate pyroptosis and lipid peroxidation in early brain injury after subarachnoid hemorrhage via NLRP3 inflammasome and NF-κB pathway Redox Biol 2023 68 102960 10.1016/j.redox.2023.102960 37979447 PMC10694315 Zheng C Li W Ali T Peng Z Liu J Pan Z et al. Ibrutinib Delays ALS Installation and Increases Survival of SOD1G93A Mice by Modulating PI3K/mTOR/Akt Signaling J Neuroimmune Pharmacol 2023 18 383 96 10.1007/s11481-023-10068-9 37326908 Zhan Y Krafft PR Lekic T Ma Q Souvenir R Zhang JH et al. Imatinib preserves blood-brain barrier integrity following experimental subarachnoid hemorrhage in rats J Neurosci Res 2015 93 94 103 10.1002/jnr.23475 25196554 PMC4237717 Shiba M Fujimoto M Kawakita F Imanaka-Yoshida K Yoshida T Kanamaru K et al. Effects of tenascin-C on early brain injury after subarachnoid hemorrhage in rats Acta Neurochir Suppl 2015 120 69 73 10.1007/978-3-319-04981-6_12 25366602 Changlong Z Guangwei Z Xuenong H Xiaohui X Xiaochuan S Yanfeng X The Role of Platelet-Derived Growth Factor Receptor in Early Brain Injury Following Subarachnoid Hemorrhage J Stroke Cerebrovasc Dis 2016 25 2203 8 10.1016/j.jstrokecerebrovasdis.2016.03.025 27397729 Shiba M Fujimoto M Imanaka-Yoshida K Yoshida T Taki W Suzuki H Tenascin-C causes neuronal apoptosis after subarachnoid hemorrhage in rats Transl Stroke Res 2014 5 238 47 10.1007/s12975-014-0333-2 24481545 Shiba M Suzuki H Fujimoto M Shimojo N Imanaka-Yoshida K Yoshida T et al. Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats Neurobiol Dis 2012 46 172 9 10.1016/j.nbd.2012.01.005 22300707 Shiba M Suzuki H Fujimoto M Shimojo N Imanaka-Yoshida K Yoshida T et al. Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats Acta Neurochir Suppl 2013 115 219 23 10.1007/978-3-7091-1192-5_40 22890672 Ma Q Huang B Khatibi N Rolland W 2nd Suzuki H Zhang JH, et al. PDGFR-α inhibition preserves blood-brain barrier after intracerebral hemorrhage Ann Neurol 2011 70 920 31 10.1002/ana.22549 22190365 PMC3405848 Yang P Manaenko A Xu F Miao L Wang G Hu X et al. Role of PDGF-D and PDGFR-β in neuroinflammation in experimental ICH mice model Exp Neurol 2016 283 157 64 10.1016/j.expneurol.2016.06.010 27302678 PMC5175487 Yang P Wu J Miao L Manaenko A Matei N Zhang Y et al. Platelet-Derived Growth Factor Receptor-β Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice Crit Care Med 2016 44 e390 402 10.1097/CCM.0000000000001425 26646459 PMC4868636 Pearce WJ Doan C Carreon D Kim D Durrant LM Manaenko A et al. Imatinib attenuates cerebrovascular injury and phenotypic transformation after intracerebral hemorrhage in rats Am J Physiol Regul Integr Comp Physiol 2016 311 R1093 104 10.1152/ajpregu.00240.2016 27707720 PMC5256978 Ding J Lian J Wang J Yang S Li H Shen H et al. The role of Tenascin C in intracerebral hemorrhage-induced secondary brain injury in rats via induction of neuronal cell death and neuroinflammation J Chem Neuroanat 2022 125 102147 10.1016/j.jchemneu.2022.102147 36028204 Sun Z Gao C Gao D Sun R Li W Wang F et al. Reduction in pericyte coverage leads to blood-brain barrier dysfunction via endothelial transcytosis following chronic cerebral hypoperfusion Fluids Barriers CNS 2021 18 21 10.1186/s12987-021-00255-2 33952281 PMC8101037 Sakai K Takata F Yamanaka G Yasunaga M Hashiguchi K Tominaga K et al. Reactive pericytes in early phase are involved in glial activation and late-onset hypersusceptibility to pilocarpine-induced seizures in traumatic brain injury model mice J Pharmacol Sci 2021 145 155 65 10.1016/j.jphs.2020.11.008 33357774 Klement W Blaquiere M Zub E deBock F Boux F Barbier E et al. A pericyte-glia scarring develops at the leaky capillaries in the hippocampus during seizure activity Epilepsia 2019 60 1399 411 10.1111/epi.16019 31135065 Singh S Singh TG Imatinib Attenuates Pentylenetetrazole Kindled and Pilocarpine Induced Recurrent Spontaneous Seizures in Mice Neurochem Res 2023 48 418 34 10.1007/s11064-022-03758-y 36239857 Su EJ Fredriksson L Kanzawa M Moore S Folestad E Stevenson TK et al. Imatinib treatment reduces brain injury in a murine model of traumatic brain injury Front Cell Neurosci 2015 9 385 10.3389/fncel.2015.00385 26500491 PMC4596067 Wang J Bai T Wang N Li H Guo X Neuroprotective potential of Imatinib in global ischemia-reperfusion-induced cerebral injury: possible role of Janus-activated kinase 2/signal transducer and activator of transcription 3 and connexin 43 Korean J Physiol Pharmacol 2020 24 11 8 10.4196/kjpp.2020.24.1.11 31908570 PMC6940502 Merali Z Leung J Mikulis D Silver F Kassner A Longitudinal assessment of Imatinib’s effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI Transl Stroke Res 2015 6 39 49 10.1007/s12975-014-0358-6 25146090 Torrente D Su EJ Fredriksson L Warnock M Bushart D Mann KM et al. Compartmentalized Actions of the Plasminogen Activator Inhibitors, PAI-1 and Nsp, in Ischemic Stroke Transl Stroke Res 2022 13 801 15 10.1007/s12975-022-00992-y 35122213 PMC9349468 Gardner LE White JD Eimerbrink MJ Boehm GW Chumley MJ Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide Neuroscience 2016 331 72 7 10.1016/j.neuroscience.2016.06.007 27320209 Weintraub MK Bisson CM Nouri JN Vinson BT Eimerbrink MJ Kranjac D et al. Imatinib methanesulfonate reduces hippocampal amyloid-beta and restores cognitive function following repeated endotoxin exposure Brain Behav Immun 2013 33 24 8 10.1016/j.bbi.2013.05.002 23665252 Sun W Netzer WJ Sinha A Gindinova K Chang E Sinha SC Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins J Med Chem 2019 62 3122 34 10.1021/acs.jmedchem.8b02007 30873837 Bauer C Pardossi-Piquard R Dunys J Roy M Checler F γ-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by Imatinib J Alzheimers Dis 2011 27 511 20 10.3233/JAD-2011-110746 21841248 Sutcliffe JG Hedlund PB Thomas EA Bloom FE Hilbush BS Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer’s disease J Neurosci Res 2011 89 808 14 10.1002/jnr.22603 21374699 Hussain I Fabrègue J Anderes L Ousson S Borlat F Eligert V et al. The role of γ-secretase activating protein (GSAP) and Imatinib in the regulation of γ-secretase activity and amyloid-β generation J Biol Chem 2013 288 2521 31 10.1074/jbc.M112.370924 23209290 PMC3554920 Netzer WJ Bettayeb K Sinha SC Flajolet M Greengard P Bustos V Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage Proc Natl Acad Sci U S A 2017 114 1389 94 10.1073/pnas.1620963114 28115709 PMC5307477 Estrada LD Chamorro D Yañez MJ Gonzalez M Leal N von Bernhardi R et al. Reduction of Blood Amyloid-β Oligomers in Alzheimer’s Disease Transgenic Mice by c-Abl Kinase Inhibition J Alzheimers Dis 2016 54 1193 205 10.3233/JAD-151087 27567806 Netzer WJ Dou F Cai D Veach D Jean S Li Y et al. Gleevec inhibits β-amyloid production but not Notch cleavage Proc Natl Acad Sci U S A 2003 100 12444 9 10.1073/pnas.1534745100 14523244 PMC218777 Chu J Lauretti E Craige CP Praticò D Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer’s disease with plaques and tangles J Alzheimers Dis 2014 41 729 37 10.3233/JAD-140105 24662099 Alvarez AR Sandoval PC Leal NR Castro PU Kosik KS Activation of the neuronal c-Abl tyrosine kinase by amyloid-β-peptide and reactive oxygen species Neurobiol Dis 2004 17 326 36 10.1016/j.nbd.2004.06.007 15474370 Cancino GI Toledo EM Leal NR Hernandez DE Yévenes LF Inestrosa NC et al. STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer’s β-amyloid deposits Brain 2008 131 2425 42 10.1093/brain/awn125 18559370 Kerridge C Belyaev ND Nalivaeva NN Turner AJ The Aβ-clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain J Neurochem 2014 130 419 31 10.1111/jnc.12680 24528201 He G Luo W Li P Remmers C Netzer WJ Hendrick J et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease Nature 2010 467 95 8 10.1038/nature09325 20811458 PMC2936959 Reichenstein M Borovok N Sheinin A Brider T Michaelevski I Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1-42 Peptides Cell Mol Neurobiol 2021 41 431 48 10.1007/s10571-020-00858-7 32399753 PMC11448580 Lee HJ Hoe HS Repurposing ibrutinib: therapeutic effects and implications for translational approaches in Alzheimer’s disease Neural Regen Res 2023 18 2194 5 10.4103/1673-5374.369108 37056133 PMC10328294 Peng Q Zhang M Shi G High-Performance Extended-Gate Field-Effect Transistor for Kinase Sensing in Aβ Accumulation of Alzheimer’s Disease Anal Chem 2022 94 1491 7 10.1021/acs.analchem.1c05164 34985875 Netzer WJ Sinha A Ghias M Chang E Gindinova K Mui E et al. Stretching the structural envelope of Imatinib to reduce β-amyloid production by modulating both β- and γ-secretase cleavages of APP Front Chem 2024 12 1381205 10.3389/fchem.2024.1381205 39439934 PMC11493595 Ren Y Chen J Wu X Gui C Mao K Zou F et al. Role of c-Abl-GSK3β Signaling in MPP+-Induced Autophagy-Lysosomal Dysfunction Toxicol Sci 2018 165 232 43 10.1093/toxsci/kfy155 30165626 Wu R Chen H Ma J He Q Huang Q Liu Q et al. c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death Cell Death Differ 2016 23 542 52 10.1038/cdd.2015.135 26517532 PMC5072446 Imam SZ Zhou Q Yamamoto A Valente AJ Ali SF Bains M et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson’s disease J Neurosci 2011 31 157 63 10.1523/JNEUROSCI.1833-10.2011 21209200 PMC3039694 Yamamura Y Morigaki R Kasahara J Yokoyama H Tanabe A Okita S et al. Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice Front Cell Neurosci 2013 7 12 10.3389/fncel.2013.00012 23420105 PMC3572678 Marín T Valls C Jerez C Huerta T Elgueta D Vidal RL et al. The c-Abl/p73 pathway induces neurodegeneration in a Parkinson’s disease model IBRO Neurosci Rep 2022 13 378 87 10.1016/j.ibneur.2022.10.006 36590096 PMC9795287 Rusiecka I Gągało I Kocić I Neuroprotective Activity of a Non-Covalent Imatinib+TP10 Conjugate in HT-22 Neuronal Cells In Vitro Pharmaceutics 2024 16 778 10.3390/pharmaceutics16060778 38931899 PMC11207969 Pan Y Sun L Wang J Fu W Fu Y Wang J et al. STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis Neuropharmacology 2015 93 191 8 10.1016/j.neuropharm.2015.01.029 25681617 Aguib Y Heiseke A Gilch S Riemer C Baier M Schätzl HM et al. Autophagy induction by trehalose counter-acts cellular prion infection Autophagy 2009 5 361 9 10.4161/auto.5.3.7662 19182537 Yun SW Ertmer A Flechsig E Gilch S Riederer P Gerlach M et al. The tyrosine kinase inhibitor Imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery J Neurovirol 2007 13 328 37 10.1080/13550280701361516 17849316 Ertmer A Gilch S Yun SW Flechsig E Klebl B Stein-Gerlach M et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells J Biol Chem 2004 279 41918 27 10.1074/jbc.M405652200 15247213 Rojas F Gonzalez D Cortes N Ampuero E Hernández DE Fritz E et al. Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling Front Cell Neurosci 2015 9 203 10.3389/fncel.2015.00203 26106294 PMC4460879 Kegel KB Sapp E Alexander J Reeves P Bleckmann D Sobin L et al. Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors Mol Neurodegener 2010 5 58 10.1186/1750-1326-5-58 21156064 PMC3018386 Nacer A Movila A Baer K Mikolajczak SA Kappe SH Frevert U Neuroimmunological blood brain barrier opening in experimental cerebral malaria PLoS Pathog 2012 8 e1002982 10.1371/journal.ppat.1002982 23133375 PMC3486917 Vlasic V Simakajornboon N Gozal E Gozal D PDGF-β receptor expression in the dorsocaudal brainstem parallels hypoxic ventilatory depression in the developing rat Pediatr Res 2001 50 236 41 10.1203/00006450-200108000-00012 11477209 Yáñez MJ Belbin O Estrada LD Leal N Contreras PS Lleó A et al. c-Abl links APP-BACE1 interaction promoting APP amyloidogenic processing in Niemann-Pick type C disease Biochim Biophys Acta 2016 1862 2158 67 10.1016/j.bbadis.2016.08.016 27565738 Marín T Dulcey AE Campos F de la Fuente C Acuña M Castro J et al. c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease Front Cell Dev Biol 2022 10 844297 10.3389/fcell.2022.844297 35399514 PMC8985125 Yañez MJ Campos F Marín T Klein AD Futerman AH Alvarez AR et al. c-Abl activates RIPK3 signaling in Gaucher disease Biochim Biophys Acta Mol Basis Dis 2021 1867 166089 10.1016/j.bbadis.2021.166089 33549745 Potula R Dhillion N Sui Y Zien CA Funa K Pinson D et al. Association of platelet-derived growth factor-B chain with simian human immunodeficiency virus encephalitis Am J Pathol 2004 165 815 24 10.1016/S0002-9440(10)63344-5 15331406 PMC1618609 Jia X Zhang A Li Z Peng X Tian X Gao F Activation of spinal PDGFRβ in microglia promotes neuronal autophagy via p38 MAPK pathway in morphine-tolerant rats J Neurochem 2021 158 373 90 10.1111/jnc.15383 33950542 Shang J Li W Zhang H Wang W Liu N Gao D et al. C-kit controls blood-brain barrier permeability by regulating caveolae-mediated transcytosis after chronic cerebral hypoperfusion Biomed Pharmacother 2024 170 115778 10.1016/j.biopha.2023.115778 38141279 Pokharel S Gliyazova NS Dandepally SR Williams AL Ibeanu GC Neuroprotective effects of an in vitro BBB permeable phenoxythiophene sulfonamide small molecule in glutamate-induced oxidative injury Exp Ther Med 2022 23 79 10.3892/etm.2021.11002 34938365 PMC8688931 Rezzola S Guerra J Krishna Chandran AM Loda A Cancarini A Sacristani P et al. VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients Int J Mol Sci 2021 22 2179 10.3390/ijms22042179 33671690 PMC7926720 Rajendran R Rajendran V Böttiger G Stadelmann C Shirvanchi K von Au L et al. The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti-inflammatory effects and remyelination in a model of multiple sclerosis Br J Pharmacol 2023 180 2989 3007 10.1111/bph.16186 37400950 Jia JN Yin XX Li Q Guan QW Yang N Chen KN et al. Neuroprotective Effects of the Anti-cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis Front Pharmacol 2020 11 601572 10.3389/fphar.2020.601572 33362556 PMC7758233 Xu HY Sun YJ Sun YY Wu YJ Xu MY Chen LP et al. Lapatinib alleviates TOCP-induced axonal damage in the spinal cord of mouse Neuropharmacology 2021 189 108535 10.1016/j.neuropharm.2021.108535 33766630 Mansour HM Fawzy HM El-Khatib AS Khattab MM Lapatinib ditosylate rescues memory impairment in D-galactose/ovariectomized rats: Potential repositioning of an anti-cancer drug for the treatment of Alzheimer’s disease Exp Neurol 2021 341 113697 10.1016/j.expneurol.2021.113697 33727095 Mansour HM Fawzy HM El-Khatib AS Khattab MM Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates Alzheimer’s-like disease in D-galactose/ovariectomized rats Neurochem Int 2021 150 105178 10.1016/j.neuint.2021.105178 34481907 Mansour HM Mohamed AF Khattab MM El-Khatib AS Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation of dopamine D3 receptor Brain Res 2024 1834 148893 10.1016/j.brainres.2024.148893 38554797 Saul S Karim M Ghita L Huang PT Chiu W Durán V et al. Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects J Clin Invest 2023 133 e169510 10.1172/JCI169510 37581931 PMC10541190 Zavvarian MM Hong J Khazaei M Chio JCT Wang J Badner A et al. The Protein Kinase Inhibitor Midostaurin Improves Functional Neurological Recovery and Attenuates Inflammatory Changes Following Traumatic Cervical Spinal Cord Injury Biomolecules 2021 11 972 10.3390/biom11070972 34356596 PMC8301989 Esteban-Martos A Brokate-Llanos AM Real LM Melgar-Locatelli S de Rojas I Castro-Zavala A et al. A Functional Pipeline of Genome-Wide Association Data Leads to Midostaurin as a Repurposed Drug for Alzheimer’s Disease Int J Mol Sci 2023 24 12079 10.3390/ijms241512079 37569459 PMC10418421 Dent P Booth L Roberts JL Poklepovic A Cridebring D Reiman EM Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43 Aging (Albany NY) 2021 13 17097 117 10.18632/aging.203297 34252884 PMC8312464 Dent P Booth L Roberts JL Poklepovic A Martinez J Cridebring D et al. AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy Aging (Albany NY) 2022 14 8221 42 10.18632/aging.204337 36227739 PMC9648812 Kitaoka Y Sase K Tsukahara C Fujita N Arizono I Kogo J et al. Axonal Protection by Netarsudil, a ROCK Inhibitor, Is Linked to an AMPK-Autophagy Pathway in TNF-Induced Optic Nerve Degeneration Invest Ophthalmol Vis Sci 2022 63 4 10.1167/iovs.63.1.4 34982146 PMC8742515 Attia GM Elmansy RA Elsaed WM Neuroprotective effect of nilotinib on pentylenetetrazol-induced epilepsy in adult rat hippocampus: involvement of oxidative stress, autophagy, inflammation, and apoptosis Folia Neuropathol 2019 57 146 60 10.5114/fn.2019.84423 31556574 Lonskaya I Hebron M Chen W Schachter J Moussa C Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models Mol Neurodegener 2014 9 46 10.1186/1750-1326-9-46 25384392 PMC4247762 Liu X Hebron M Shi W Lonskaya I Moussa CE Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies Hum Mol Genet 2019 28 548 60 10.1093/hmg/ddy365 30329047 Mahul-Mellier AL Fauvet B Gysbers A Dikiy I Oueslati A Georgeon S et al. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease Hum Mol Genet 2014 23 2858 79 10.1093/hmg/ddt674 24412932 PMC4014189 Imberdis T Negri J Ramalingam N Terry-Kantor E Ho GPH Fanning S et al. Cell models of lipid-rich α-synuclein aggregation validate known modifiers of α-synuclein biology and identify stearoyl-CoA desaturase Proc Natl Acad Sci U S A 2019 116 20760 9 10.1073/pnas.1903216116 31548371 PMC6789936 Adlimoghaddam A Odero GG Glazner G Turner RS Albensi BC Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer’s Disease Aging Dis 2021 12 441 65 10.14336/AD.2020.0910 33815876 PMC7990369 La Barbera L Vedele F Nobili A Krashia P Spoleti E Latagliata EC et al. Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer’s Disease Prog Neurobiol 2021 202 102031 10.1016/j.pneurobio.2021.102031 33684513 Nobili A La Barbera L D’Amelio M Targeting autophagy as a therapeutic strategy to prevent dopamine neuron loss in early stages of Alzheimer disease Autophagy 2021 17 1278 80 10.1080/15548627.2021.1909409 33779492 PMC8143232 Wu J Xu X Zheng L Mo J Jin X Bao Y Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson’s disease models Int Immunopharmacol 2021 99 108025 10.1016/j.intimp.2021.108025 34364303 Kuo YC Tsai HC Rajesh R Glutathione Liposomes Carrying Ceftriaxone, FK506, and Nilotinib to Control Overexpressed Dopamine Markers and Apoptotic Factors in Neurons ACS Biomater Sci Eng 2021 7 3242 55 10.1021/acsbiomaterials.1c00555 34189904 Kim H Shin JY Jo A Kim JH Park S Choi JY et al. Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration Brain 2021 144 3674 91 10.1093/brain/awab356 34581802 PMC8719843 Peikert K Federti E Matte A Constantin G Pietronigro EC Fabene PF et al. Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis Acta Neuropathol Commun 2021 9 81 10.1186/s40478-021-01181-y 33941276 PMC8091687 Federti E Matte A Riccardi V Peikert K Alper SL Danek A et al. Adaptative Up-Regulation of PRX2 and PRX5 Expression Characterizes Brain from a Mouse Model of Chorea-Acanthocytosis Antioxidants (Basel) 2021 11 76 10.3390/antiox11010076 35052580 PMC8772732 Kim J Lee HJ Park JH Cha BY Hoe HS Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling J Neuroinflammation 2022 19 187 10.1186/s12974-022-02549-0 35841100 PMC9288088 Unterman I Bloch I Cazacu S Kazimirsky G Ben-Zeev B Berman BP et al. Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome Elife 2021 10 e67085 10.7554/eLife.67085 34355696 PMC8346285 Campbell GR Rawat P Teodorof-Diedrich C Spector SA IRAK1 inhibition blocks the HIV-1 RNA mediated pro-inflammatory cytokine response from microglia J Gen Virol 2023 104 001858 10.1099/jgv.0.001858 37256770 PMC10336426 Hor JH Soh ES Tan LY Lim VJW Santosa MM Winanto et al. Cell cycle inhibitors protect motor neurons in an organoid model of Spinal Muscular Atrophy Cell Death Dis 2018 9 1100 10.1038/s41419-018-1081-0 30368521 PMC6204135 Chao AC Chen CH Chang SH Huang CT Hwang WC Yang DI Id1 and Sonic Hedgehog Mediate Cell Cycle Reentry and Apoptosis Induced by Amyloid Beta-Peptide in Post-mitotic Cortical Neurons Mol Neurobiol 2019 56 465 89 10.1007/s12035-018-1098-5 29721855 Esteras N Alquézar C Bartolomé F de la Encarnación A Bermejo-Pareja F Molina JA et al. G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson’s Disease Patients Mol Neurobiol 2015 52 386 98 10.1007/s12035-014-8870-y 25182869 Javidnia M Hebron ML Xin Y Kinney NG Moussa CE Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy J Alzheimers Dis 2017 60 461 81 10.3233/JAD-170429 28869476 PMC5757517 Yang Y Li G Zhao D Yu H Zheng X Peng X et al. Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration Chem Sci 2015 6 2812 21 10.1039/c4sc03416c 28706670 PMC5489033 Ma K Pham T Wang J O-Sullivan I DiCamillo A Du S et al. Nanoparticle-based inhibition of vascular endothelial growth factor receptors alleviates osteoarthritis pain and cartilage damage Sci Adv 2024 10 eadi5501 10.1126/sciadv.adi5501 38354243 PMC10866538 Mansour HM Mohamed AF Khattab MM El-Khatib AS Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms Food Chem Toxicol 2023 181 114069 10.1016/j.fct.2023.114069 37820786 Sun HY Wu J Wang R Zhang S Xu H Kaznacheyeva Е et al. Pazopanib alleviates neuroinflammation and protects dopaminergic neurons in LPS-stimulated mouse model by inhibiting MEK4-JNK-AP-1 pathway Acta Pharmacol Sin 2023 44 1135 48 10.1038/s41401-022-01030-1 36536076 PMC10203146 Abdelhady R Younis NS Ali O Shehata S Sayed RH Nadeem RI Cognitive enhancing effects of pazopanib in D‑galactose/ovariectomized Alzheimer’s rat model: insights into the role of RIPK1/RIPK3/MLKL necroptosis signaling pathway Inflammopharmacology 2023 31 2719 29 10.1007/s10787-023-01269-y 37458952 PMC10518286 Li M Li Z Ren H Jin WN Wood K Liu Q et al. Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage J Cereb Blood Flow Metab 2017 37 2383 95 10.1177/0271678X16666551 27596835 PMC5482387 Shi E Shi K Qiu S Sheth KN Lawton MT Ducruet AF Chronic inflammation, cognitive impairment, and distal brain region alteration following intracerebral hemorrhage FASEB J 2019 33 9616 26 10.1096/fj.201900257R 31145859 Li X Gao X Zhang W Liu M Han Z Li M et al. Microglial replacement in the aged brain restricts neuroinflammation following intracerebral hemorrhage Cell Death Dis 2022 13 33 10.1038/s41419-021-04424-x 35013119 PMC8748975 Heinz R Brandenburg S Nieminen-Kelhä M Kremenetskaia I Boehm-Sturm P Vajkoczy P et al. Microglia as target for anti-inflammatory approaches to prevent secondary brain injury after subarachnoid hemorrhage (SAH) J Neuroinflammation 2021 18 36 10.1186/s12974-021-02085-3 33516246 PMC7847606 Shen Q Zhang G Depletion of microglia mitigates cerebrovascular dysfunction in diet-induced obesity mice Am J Physiol Endocrinol Metab 2021 321 E367 75 10.1152/ajpendo.00086.2021 34338040 Rice RA Spangenberg EE Yamate-Morgan H Lee RJ Arora RP Hernandez MX et al. Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus J Neurosci 2015 35 9977 89 10.1523/JNEUROSCI.0336-15.2015 26156998 PMC4495246 Shi Y Manis M Long J Wang K Sullivan PM Remolina Serrano J et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model J Exp Med 2019 216 2546 61 10.1084/jem.20190980 31601677 PMC6829593 Sosna J Philipp S Albay R 3rd Reyes-Ruiz JM Baglietto-Vargas D LaFerla FM et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease Mol Neurodegener 2018 13 11 10.1186/s13024-018-0244-x 29490706 PMC5831225 Son Y Jeong YJ Shin NR Oh SJ Nam KR Choi HD et al. Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice Int J Mol Sci 2020 21 5553 10.3390/ijms21155553 32756440 PMC7432084 Crapser JD Ochaba J Soni N Reidling JC Thompson LM Green KN Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington’s disease Brain 2020 143 266 88 10.1093/brain/awz363 31848580 PMC6935750 Tahmasebi F Pasbakhsh P Mortezaee K Madadi S Barati S Kashani IR Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model J Cell Biochem 2019 120 10576 86 10.1002/jcb.28344 30628737 Groh J Klein D Berve K West BL Martini R Targeting microglia attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations Glia 2019 67 277 90 10.1002/glia.23539 30565754 Tahmasebi F Pasbakhsh P Barati S Madadi S Kashani IR The effect of microglial ablation and mesenchymal stem cell transplantation on a cuprizone-induced demyelination model J Cell Physiol 2021 236 3552 64 10.1002/jcp.30090 32996165 Qu W Johnson A Kim JH Lukowicz A Svedberg D Cvetanovic M Inhibition of colony-stimulating factor 1 receptor early in disease ameliorates motor deficits in SCA1 mice J Neuroinflammation 2017 14 107 10.1186/s12974-017-0880-z 28545543 PMC5445366 Pinto B Morelli G Rastogi M Savardi A Fumagalli A Petretto A et al. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome Neuron 2020 108 887 904 10.1016/j.neuron.2020.09.010 33027640 PMC7736620 Ueta Y Miyata M Brainstem local microglia induce whisker map plasticity in the thalamus after peripheral nerve injury Cell Rep 2021 34 108823 10.1016/j.celrep.2021.108823 33691115 da Silva MCM Gomes GF de Barros Fernandes H da Silva AM Teixeira AL Moreira FA et al. Inhibition of CSF1R, a receptor involved in microglia viability, alters behavioral and molecular changes induced by cocaine Sci Rep 2021 11 15989 10.1038/s41598-021-95059-7 34362959 PMC8346567 Zhang D Li S Hou L Jing L Ruan Z Peng B et al. Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson’s disease model J Neuroinflammation 2021 18 4 10.1186/s12974-020-02065-z 33402167 PMC7786472 Stoll AC Kemp CJ Patterson JR Kubik M Kuhn N Benskey M et al. Microglial depletion does not impact alpha-synuclein aggregation or nigrostriatal degeneration in the rat preformed fibril model Res Sq 2890683 [Preprint]. 2023 [cited 2025 May 26]. Available from: https://www.researchsquare.com/article/rs-2890683/v1 Stoll AC Kemp CJ Patterson JR Kubik M Kuhn N Benskey M et al. Alpha-synuclein inclusion responsive microglia are resistant to CSF1R inhibition J Neuroinflammation 2024 21 108 10.1186/s12974-024-03108-5 38664840 PMC11045433 Ni RJ Wang YY Gao TH Wang QR Wei JX Zhao LS et al. Depletion of microglia with PLX3397 attenuates MK-801-induced hyperactivity associated with regulating inflammation-related genes in the brain Zool Res 2023 44 543 55 10.24272/j.issn.2095-8137.2022.389 37147908 PMC10236309 Xie ST Fan WC Zhao XS Ma XY Li ZL Zhao YR et al. Proinflammatory activation of microglia in the cerebellum hyperexcites Purkinje cells to trigger ataxia Pharmacol Res 2023 191 106773 10.1016/j.phrs.2023.106773 37068531 Spencer KA Mulholland M Snell J Howe M James K Hanaford AR et al. Volatile anaesthetic toxicity in the genetic mitochondrial disease Leigh syndrome Br J Anaesth 2023 131 832 46 10.1016/j.bja.2023.08.009 37770252 PMC10636522 Daneshgar N Leidinger MR Le S Hefti M Prigione A Dai DF Activated microglia and neuroinflammation as a pathogenic mechanism in Leigh syndrome Front Neurosci 2023 16 1068498 10.3389/fnins.2022.1068498 36741056 PMC9889986 El Jordi O Fischer KD Meyer TB Atwood BK Oblak AL Pan RW et al. Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice Adv Drug Alcohol Res 2022 2 10848 10.3389/adar.2022.10848 38390615 PMC10880796 Wang L Wang X Deng L Zhang H He B Cao W et al. Pexidartinib (PLX3397) through restoring hippocampal synaptic plasticity ameliorates social isolation-induced mood disorders Int Immunopharmacol 2022 113 109436 10.1016/j.intimp.2022.109436 36395673 PMC9661988 Wang Y Wernersbach I Strehle J Li S Appel D Klein M et al. Early posttraumatic CSF1R inhibition via PLX3397 leads to time- and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice Brain Behav Immun 2022 106 49 66 10.1016/j.bbi.2022.07.164 35933030 Saika F Fukazawa Y Hatano Y Kishioka S Hino Y Hino S et al. Sexually dimorphic effects of pexidartinib on nerve injury-induced neuropathic pain in mice Glia 2024 72 1402 17 10.1002/glia.24535 38591338 Tian J Guo S Chen H Peng JJ Jia MM Li NS et al. Combination of Emricasan with Ponatinib Synergistically Reduces Ischemia/Reperfusion Injury in Rat Brain Through Simultaneous Prevention of Apoptosis and Necroptosis Transl Stroke Res 2018 9 382 92 10.1007/s12975-017-0581-z 29103102 Zhang Y Zhang M Zhu W Pan X Wang Q Gao X et al. Role of Elevated Thrombospondin-1 in Kainic Acid-Induced Status Epilepticus Neurosci Bull 2020 36 263 76 10.1007/s12264-019-00437-x 31664678 PMC7056766 Choi JP Wang R Yang X Wang X Wang L Ting KK et al. Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations Sci Adv 2018 4 eaau0731 10.1126/sciadv.aau0731 30417093 PMC6221540 Han KM Kang RJ Jeon H Lee HJ Lee JS Park H et al. Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD Cells 2020 9 1655 10.3390/cells9071655 32660121 PMC7408082 Maher P Conti B Deciphering the pathways that protect from IL-13-mediated potentiation of oxidative stress-induced dopaminergic nerve cell death Cytokine 2018 103 114 20 10.1016/j.cyto.2017.09.018 28969943 PMC5808859 Hosseini A Gharibi T Mohammadzadeh A Ebrahimi-Kalan A Jadidi-Niaragh F Babaloo Z et al. Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS) Life Sci 2021 276 119395 10.1016/j.lfs.2021.119395 33781828 Yu X Lv J Wu J Chen Y Chen F Wang L The autoimmune encephalitis-related cytokine TSLP in the brain primes neuroinflammation by activating the JAK2-NLRP3 axis Clin Exp Immunol 2022 207 113 22 10.1093/cei/uxab023 35020848 PMC8802176 Sharma S Risen S Gilberto VS Boland S Chatterjee A Moreno JA et al. Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in an Experimental Autoimmune Encephalomyelitis Mouse Model ACS Chem Neurosci 2024 15 1596 608 10.1021/acschemneuro.4c00024 38526238 Sullivan KD Lewis HC Hill AA Pandey A Jackson LP Cabral JM et al. Trisomy 21 consistently activates the interferon response Elife 2016 5 e16220 10.7554/eLife.16220 27472900 PMC5012864 Takata F Dohgu S Sakaguchi S Sakai K Yamanaka G Iwao T et al. Oncostatin-M-Reactive Pericytes Aggravate Blood-Brain Barrier Dysfunction by Activating JAK/STAT3 Signaling In Vitro Neuroscience 2019 422 12 20 10.1016/j.neuroscience.2019.10.014 31705893 Haile WB Gavegnano C Tao S Jiang Y Schinazi RF Tyor WR The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model Neurobiol Dis 2016 92 137 43 10.1016/j.nbd.2016.02.007 26851503 PMC4907871 Zhang J He H Qiao Y Zhou T He H Yi S et al. Priming of microglia with IFN-γ impairs adult hippocampal neurogenesis and leads to depression-like behaviors and cognitive defects Glia 2020 68 2674 92 10.1002/glia.23878 32652855 Chen X Gao C Yan Y Cheng Z Chen G Rui T et al. Ruxolitinib exerts neuroprotection via repressing ferroptosis in a mouse model of traumatic brain injury Exp Neurol 2021 342 113762 10.1016/j.expneurol.2021.113762 33991524 Peng J Gao C Chen X Wang T Luo C Zhang M et al. Ruxolitinib, a promising therapeutic candidate for traumatic brain injury through maintaining the homeostasis of cathepsin B Exp Neurol 2023 363 114347 10.1016/j.expneurol.2023.114347 36813222 Zhu H Jian Z Zhong Y Ye Y Zhang Y Hu X et al. Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition Front Immunol 2021 12 714943 10.3389/fimmu.2021.714943 34367186 PMC8339584 Qian ZY Kong RY Zhang S Wang BY Chang J Cao J et al. Ruxolitinib attenuates secondary injury after traumatic spinal cord injury Neural Regen Res 2022 17 2029 35 10.4103/1673-5374.335165 35142693 PMC8848590 Cao J Yu X Liu J Fu J Wang B Wu C et al. Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury Neural Regen Res 2024 19 2499 512 10.4103/NRR.NRR-D-23-01863 38526286 PMC11090442 Passos V Henkel LM Wang J Zapatero-Belinchón FJ Möller R Sun G et al. Innate immune response to SARS-CoV-2 infection contributes to neuronal damage in human iPSC-derived peripheral neurons J Med Virol 2024 96 e29455 10.1002/jmv.29455 38323709 Alquezar C Esteras N de la Encarnación A Moreno F López de Munain A Martín-Requero Á Increasing progranulin levels and blockade of the ERK1/2 pathway: upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia Eur Neuropsychopharmacol 2015 25 386 403 10.1016/j.euroneuro.2014.12.007 25624003 Ullrich M Weber M Post AM Popp S Grein J Zechner M et al. OCD-like behavior is caused by dysfunction of thalamo-amygdala circuits and upregulated TrkB/ERK-MAPK signaling as a result of SPRED2 deficiency Mol Psychiatry 2018 23 444 58 10.1038/mp.2016.232 28070119 PMC5794898 Huang HJ Wang HT Yeh TY Lin BW Shiao YJ Lo YL et al. Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity Sci Rep 2021 11 12497 10.1038/s41598-021-91507-6 34127699 PMC8203693 Fei X Dou YN Wang L Wu X Huan Y Wu S et al. Homer1 promotes the conversion of A1 astrocytes to A2 astrocytes and improves the recovery of transgenic mice after intracerebral hemorrhage J Neuroinflammation 2022 19 67 10.1186/s12974-022-02428-8 35287697 PMC8922810 Talebi A Rahnema M Bigdeli MR Effect of intravenous injection of antagomiR-1 on brain ischemia Mol Biol Rep 2019 46 1149 55 10.1007/s11033-018-04580-y 30707419 Guo W Feng G Miao Y Liu G Xu C Rapamycin alleviates brain edema after focal cerebral ischemia reperfusion in rats Immunopharmacol Immunotoxicol 2014 36 211 23 10.3109/08923973.2014.913616 24773551 Wang J Lin X Mu Z Shen F Zhang L Xie Q et al. Rapamycin Increases Collateral Circulation in Rodent Brain after Focal Ischemia as detected by Multiple Modality Dynamic Imaging Theranostics 2019 9 4923 34 10.7150/thno.32676 31410191 PMC6691378 Chauhan A Sharma U Jagannathan NR Gupta YK Rapamycin ameliorates brain metabolites alterations after transient focal ischemia in rats Eur J Pharmacol 2015 757 28 33 10.1016/j.ejphar.2015.03.006 25814258 Chi OZ Kiss GK Mellender SJ Liu X Weiss HR Rapamycin decreased blood-brain barrier permeability in control but not in diabetic rats in early cerebral ischemia Neurosci Lett 2017 654 17 22 10.1016/j.neulet.2017.06.021 28625574 Liu P Yang X Hei C Meli Y Niu J Sun T et al. Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling Int J Biol Sci 2016 12 1032 40 10.7150/ijbs.15624 27489506 PMC4971741 Liang G Niu Y Li Y Wei A Dong J Zeng L Rapamycin treatment starting at 24 h after cerebral ischemia/reperfusion exhibits protective effect on brain injury in rats Zhejiang Da Xue Xue Bao Yi Xue Ban 2018 47 443 49. Chinese 10.3785/j.issn.1008-9292.2018.10.01 30693684 PMC10393645 Yang X Hei C Liu P Song Y Thomas T Tshimanga S et al. Inhibition of mTOR Pathway by Rapamycin Reduces Brain Damage in Rats Subjected to Transient Forebrain Ischemia Int J Biol Sci 2015 11 1424 35 10.7150/ijbs.12930 26681922 PMC4672000 Park JH Ahn JH Song M Kim H Park CW Park YE et al. A 2-Min Transient Ischemia Confers Cerebral Ischemic Tolerance in Non-Obese Gerbils, but Results in Neuronal Death in Obese Gerbils by Increasing Abnormal mTOR Activation-Mediated Oxidative Stress and Neuroinflammation Cells 2019 8 1126 10.3390/cells8101126 31546722 PMC6830098 Mehta RI Tsymbalyuk N Ivanova S Stokum JA Woo K Gerzanich V et al. α-Endosulfine (ARPP-19e) Expression in a Rat Model of Stroke J Neuropathol Exp Neurol 2017 76 898 907 10.1093/jnen/nlx074 28922851 PMC6251507 Carloni S Buonocore G Balduini W Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury Neurobiol Dis 2008 32 329 39 10.1016/j.nbd.2008.07.022 18760364 Hei C Liu P Yang X Niu J Li PA Inhibition of mTOR signaling Confers Protection against Cerebral Ischemic Injury in Acute Hyperglycemic Rats Int J Biol Sci 2017 13 878 87 10.7150/ijbs.18976 28808420 PMC5555105 Zhang B Wu M Liu L Zhu Y Kai J Zeng L Inhibiting mammalian target of rapamycin signaling pathway improves cognitive function in mice with chronic cerebral ischemia Zhejiang Da Xue Xue Bao Yi Xue Ban 2017 46 405 12. Chinese 10.3785/j.issn.1008-9292.2017.08.10 29256230 PMC10396903 Li Q Zhang T Wang J Zhang Z Zhai Y Yang GY et al. Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke Biochem Biophys Res Commun 2014 444 182 8 10.1016/j.bbrc.2014.01.032 24440703 Ghiglieri V Pendolino V Bagetta V Sgobio C Calabresi P Picconi B mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP Exp Neurol 2010 226 328 31 10.1016/j.expneurol.2010.09.012 20854816 Fletcher L Evans TM Watts LT Jimenez DF Digicaylioglu M Rapamycin treatment improves neuron viability in an in vitro model of stroke PLoS One 2013 8 e68281 10.1371/journal.pone.0068281 23861877 PMC3701663 Xia DY Li W Qian HR Yao S Liu JG Qi XK Ischemia preconditioning is neuroprotective in a rat cerebral ischemic injury model through autophagy activation and apoptosis inhibition Braz J Med Biol Res 2013 46 580 8 10.1590/1414-431X20133161 23903681 PMC3859329 Su J Zhang T Wang K Zhu T Li X Autophagy activation contributes to the neuroprotection of remote ischemic perconditioning against focal cerebral ischemia in rats Neurochem Res 2014 39 2068 77 10.1007/s11064-014-1396-x 25082119 Sheng R Zhang LS Han R Liu XQ Gao B Qin ZH Autophagy activation is associated with neuroprotection in a rat model of focal cerebral ischemic preconditioning Autophagy 2010 6 482 94 10.4161/auto.6.4.11737 20400854 Yin L Ye S Chen Z Zeng Y Rapamycin preconditioning attenuates transient focal cerebral ischemia/reperfusion injury in mice Int J Neurosci 2012 122 748 56 10.3109/00207454.2012.721827 22901235 Sheng R Liu XQ Zhang LS Gao B Han R Wu YQ et al. Autophagy regulates endoplasmic reticulum stress in ischemic preconditioning Autophagy 2012 8 310 25 10.4161/auto.18673 22361585 Fan T Huang Z Chen L Wang W Zhang B Xu Y et al. Associations between autophagy, the ubiquitin-proteasome system and endoplasmic reticulum stress in hypoxia-deoxygenation or ischemia-reperfusion Eur J Pharmacol 2016 791 157 67 10.1016/j.ejphar.2016.08.026 27568838 Carloni S Girelli S Scopa C Buonocore G Longini M Balduini W Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia Autophagy 2010 6 366 77 10.4161/auto.6.3.11261 20168088 Hwang JY Gertner M Pontarelli F Court-Vazquez B Bennett MV Ofengeim D et al. Global ischemia induces lysosomal-mediated degradation of mTOR and activation of autophagy in hippocampal neurons destined to die Cell Death Differ 2017 24 317 29 10.1038/cdd.2016.140 27935582 PMC5299717 XXie L Sun F Wang J Mao X Xie L Yang SH et al. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia J Immunol 2014 192 6009 19 10.4049/jimmunol.1303492 24829408 PMC4128178 Lu Y Li C Chen Q Liu P Guo Q Zhang Y et al. Microthrombus-Targeting Micelles for Neurovascular Remodeling and Enhanced Microcirculatory Perfusion in Acute Ischemic Stroke Adv Mater 2019 31 e1808361 10.1002/adma.201808361 30957932 QQi H Su FY Wan S Chen Y Cheng YQ Liu AJ The antiaging activity and cerebral protection of rapamycin at micro-doses CNS Neurosci Ther 2014 20 991 8 10.1111/cns.12338 25327787 PMC6493198 Chauhan A Sharma U Jagannathan NR Reeta KH Gupta YK Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats Behav Brain Res 2011 225 603 9 10.1016/j.bbr.2011.08.035 21903138 Beard DJ Li Z Schneider AM Couch Y Cipolla MJ Buchan AM Rapamycin Induces an eNOS (Endothelial Nitric Oxide Synthase) Dependent Increase in Brain Collateral Perfusion in Wistar and Spontaneously Hypertensive Rats Stroke 2020 51 2834 43 10.1161/STROKEAHA.120.029781 32772681 PMC7484020 Wang CY Kim HH Hiroi Y Sawada N Salomone S Benjamin LE et al. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR Sci Signal 2009 2 ra11 10.1126/scisignal.2000143 19293429 PMC2667954 Moradpour S Aliaghaei A Bigdeli M Effect of Sertoli Cell Transplant and Rapamycin Pretreatment on Middle Cerebral Artery Occlusion-Induced Brain Ischemia in a Rat Model Exp Clin Transplant 2021 19 1204 11 10.6002/ect.2021.0198 34812711 Wang Y Wang Y Li S Cui Y Liang X Shan J et al. Functionalized nanoparticles with monocyte membranes and rapamycin achieve synergistic chemoimmunotherapy for reperfusion-induced injury in ischemic stroke J Nanobiotechnology 2021 19 331 10.1186/s12951-021-01067-0 34674712 PMC8529766 Zhang Y Li D Gao H Zhao H Zhang S Li T Rapamycin Alleviates Neuronal Injury and Modulates Microglial Activation After Cerebral Ischemia Mol Neurobiol 2024 61 5699 717 10.1007/s12035-023-03904-9 38224443 Villa-González M Rubio M Martín-López G Mallavibarrena PR Vallés-Saiz L Vivien D et al. Pharmacological inhibition of mTORC1 reduces neural death and damage volume after MCAO by modulating microglial reactivity Biol Direct 2024 19 26 10.1186/s13062-024-00470-5 38582839 PMC10999095 Hei C Zhou Y Zhang C Gao F Cao M Yuan S et al. Rapamycin ameliorates brain damage and maintains mitochondrial dynamic balance in diabetic rats subjected to middle cerebral artery occlusion Metab Brain Dis 2023 38 409 18 10.1007/s11011-022-01020-6 35670992 Nikolaeva I Crowell B Valenziano J Meaney D D’Arcangelo G Beneficial Effects of Early mTORC1 Inhibition after Traumatic Brain Injury J Neurotrauma 2016 33 183 93 10.1089/neu.2015.3899 26122481 PMC4722609 Song Q Xie D Pan S Xu W Rapamycin protects neurons from brain contusion-induced inflammatory reaction via modulation of microglial activation Mol Med Rep 2015 12 7203 10 10.3892/mmr.2015.4407 26458361 PMC4626160 Fan YY Nan F Guo BL Liao Y Zhang MS Guo J et al. Effects of long-term rapamycin treatment on glial scar formation after cryogenic traumatic brain injury in mice Neurosci Lett 2018 678 68 75 10.1016/j.neulet.2018.05.002 29727731 Chen Y Meng J Xu Q Long T Bi F Chang C et al. Rapamycin improves the neuroprotection effect of inhibition of NLRP3 inflammasome activation after TBI Brain Res 2019 1710 163 72 10.1016/j.brainres.2019.01.005 30615886 Wang C Hu Z Zou Y Xiang M Jiang Y Botchway BOA et al. The post-therapeutic effect of rapamycin in mild traumatic brain-injured rats ensuing in the upregulation of autophagy and mitophagy Cell Biol Int 2017 41 1039 47 10.1002/cbin.10820 28685977 Erlich S Alexandrovich A Shohami E Pinkas-Kramarski R Rapamycin is a neuroprotective treatment for traumatic brain injury Neurobiol Dis 2007 26 86 93 10.1016/j.nbd.2006.12.003 17270455 Ding K Wang H Wu Y Zhang L Xu J Li T et al. Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis J Surg Res 2015 194 239 47 10.1016/j.jss.2014.09.026 25438952 Campolo M Casili G Lanza M Filippone A Cordaro M Ardizzone A et al. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury J Cell Mol Med 2021 25 7855 66 10.1111/jcmm.16702 34245104 PMC8358860 Sasaki K Yamamoto S Mutoh T Tsuru Y Taki Y Kawashima R Rapamycin protects against early brain injury independent of cerebral blood flow changes in a mouse model of subarachnoid haemorrhage Clin Exp Pharmacol Physiol 2018 45 859 62 10.1111/1440-1681.12950 29676052 Zhao H Ji Z Tang D Yan C Zhao W Gao C Role of autophagy in early brain injury after subarachnoid hemorrhage in rats Mol Biol Rep 2013 40 819 27 10.1007/s11033-012-2120-z 23054025 You W Wang Z Li H Shen H Xu X Jia G et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats J Neurol Sci 2016 367 224 31 10.1016/j.jns.2016.06.021 27423593 Li J Lu J Mi Y Shi Z Chen C Riley J et al. Voltage-dependent anion channels (VDACs) promote mitophagy to protect neuron from death in an early brain injury following a subarachnoid hemorrhage in rats Brain Res 2014 1573 74 83 10.1016/j.brainres.2014.05.021 24880016 Yamamoto S Mutoh T Sasaki K Mutoh T Taki Y Central action of rapamycin on early ischemic injury and related cardiac depression following experimental subarachnoid hemorrhage Brain Res Bull 2019 144 85 91 10.1016/j.brainresbull.2018.11.015 30481554 Jing CH Wang L Liu PP Wu C Ruan D Chen G Autophagy activation is associated with neuroprotection against apoptosis via a mitochondrial pathway in a rat model of subarachnoid hemorrhage Neuroscience 2012 213 144 53 10.1016/j.neuroscience.2012.03.055 22521819 Zhang W Khatibi NH Yamaguchi-Okada M Yan J Chen C Hu Q et al. Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines Exp Neurol 2012 233 799 806 10.1016/j.expneurol.2011.11.046 22177999 Zhang X Qin C Jing Y Yang D Liu C Gao F et al. Therapeutic effects of rapamycin and surgical decompression in a rabbit spinal cord injury model Cell Death Dis 2020 11 567 10.1038/s41419-020-02767-5 32703937 PMC7378229 Liu D Jia S Sun D Wang SY Meng FC Guo WC Rapamycin repairs damaged nerve cells and neurological function in rats with spinal cord injury through ERK signaling pathway J Biol Regul Homeost Agents 2020 34 865 73 10.23812/20-122-L-45 32689766 Wang ZY Lin JH Muharram A Liu WG Beclin-1-mediated autophagy protects spinal cord neurons against mechanical injury-induced apoptosis Apoptosis 2014 19 933 45 24623173 Song Y Xue H Liu TT Liu JM Chen D Rapamycin plays a neuroprotective effect after spinal cord injury via anti-inflammatory effects J Biochem Mol Toxicol 2015 29 29 34 10.1002/jbt.21603 25171343 Tang P Hou H Zhang L Lan X Mao Z Liu D et al. Autophagy reduces neuronal damage and promotes locomotor recovery via inhibition of apoptosis after spinal cord injury in rats Mol Neurobiol 2014 49 276 87 10.1007/s12035-013-8518-3 23954967 Goldshmit Y Kanner S Zacs M Frisca F Pinto AR Currie PD et al. Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury Mol Cell Neurosci 2015 68 82 91 10.1016/j.mcn.2015.04.006 25936601 Cordaro M Paterniti I Siracusa R Impellizzeri D Esposito E Cuzzocrea S KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice Mol Neurobiol 2017 54 2415 27 10.1007/s12035-016-9827-0 26960330 Chen HC Fong TH Hsu PW Chiu WT Multifaceted effects of rapamycin on functional recovery after spinal cord injury in rats through autophagy promotion, anti-inflammation, and neuroprotection J Surg Res 2013 179 e203 10 10.1016/j.jss.2012.02.023 22482761 Sekiguchi A Kanno H Ozawa H Yamaya S Itoi E Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice J Neurotrauma 2012 29 946 56 10.1089/neu.2011.1919 21806471 Hakim JS Rodysill BR Chen BK Schmeichel AM Yaszemski MJ Windebank AJ et al. Combinatorial tissue engineering partially restores function after spinal cord injury J Tissue Eng Regen Med 2019 13 857 73 10.1002/term.2840 30808065 PMC6529286 Xiao X Chen XY Dong YH Dong HR Zhou LN Ding YQ et al. Pre-treatment of rapamycin transformed M2 microglia alleviates traumatic cervical spinal cord injury via AIM2 signaling pathway in vitro and in vivo Int Immunopharmacol 2023 121 110394 10.1016/j.intimp.2023.110394 37295027 Shen K Li X Huang G Yuan Z Xie B Chen T et al. High rapamycin-loaded hollow mesoporous Prussian blue nanozyme targets lesion area of spinal cord injury to recover locomotor function Biomaterials 2023 303 122358 10.1016/j.biomaterials.2023.122358 37951099 Lekic T Krafft PR Klebe D Flores J Rolland WB Tang J et al. PAR-1, -4, and the mTOR Pathway Following Germinal Matrix Hemorrhage Acta Neurochir Suppl 2016 121 213 6 10.1007/978-3-319-18497-5_38 26463951 Lekic T Klebe D McBride DW Manaenko A Rolland WB Flores JJ et al. Protease-activated receptor 1 and 4 signal inhibition reduces preterm neonatal hemorrhagic brain injury Stroke 2015 46 1710 3 10.1161/STROKEAHA.114.007889 25931468 PMC4442059 Wang JP Zhang MY Role for Target of Rapamycin (mTOR) Signal Pathway in Regulating Neuronal Injury after Intracerebral Hemorrhage Cell Physiol Biochem 2017 41 145 53 10.1159/000455983 28214828 Lu Q Gao L Huang L Ruan L Yang J Huang W et al. Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat J Neuroinflammation 2014 11 44 10.1186/1742-2094-11-44 24602288 PMC3975837 Li D Liu F Yang T Jin T Zhang H Luo X et al. Rapamycin protects against neuronal death and improves neurological function with modulation of microglia after experimental intracerebral hemorrhage in rats Cell Mol Biol (Noisy-le-grand) 2016 62 67 75 27755955 Brewster AL Lugo JN Patil VV Lee WL Qian Y Vanegas F et al. Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage PLoS One 2013 8 e57808 10.1371/journal.pone.0057808 23536771 PMC3594232 Zhang H Xie Y Weng L Zhang Y Shi Q Chen T et al. Rapamycin improves learning and memory ability in ICR mice with pilocarpine-induced temporal lobe epilepsy Zhejiang Da Xue Xue Bao Yi Xue Ban 2013 42 602 8. Chinese 24421223 Raffo E Coppola A Ono T Briggs SW Galanopoulou AS A pulse rapamycin therapy for infantile spasms and associated cognitive decline Neurobiol Dis 2011 43 322 9 10.1016/j.nbd.2011.03.021 21504792 PMC3114281 Aghaie F Shemshaki A Rajabi M Khatami P Hosseini A Rapamycin alleviates memory deficit against pentylenetetrazole-induced neural toxicity in Wistar male rats Mol Biol Rep 2021 48 5083 91 10.1007/s11033-021-06504-9 34165769 Bornstein R James K Stokes J Park KY Kayser EB Snell J et al. Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy Neurobiol Dis 2022 163 105594 10.1016/j.nbd.2021.105594 34933094 PMC8770160 Codeluppi S Svensson CI Hefferan MP Valencia F Silldorff MD Oshiro M et al. The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord J Neurosci 2009 29 1093 104 10.1523/JNEUROSCI.4103-08.2009 19176818 PMC2682457 Fang B Li XQ Bao NR Tan WF Chen FS Pi XL et al. Role of autophagy in the bimodal stage after spinal cord ischemia reperfusion injury in rats Neuroscience 2016 328 107 16 10.1016/j.neuroscience.2016.04.019 27109922 Chang KT Lin YL Lin CT Hong CJ Cheng YH Tsai MJ et al. Neuroprotection in the Acute Stage Enables Functional Recovery Following Repair of Chronic Cervical Root Transection After a 3-Week Delay Neurosurgery 2020 87 823 32 10.1093/neuros/nyz572 31960049 Oku H Morishita S Horie T Kida T Mimura M Kojima S et al. P7C3 Suppresses Neuroinflammation and Protects Retinal Ganglion Cells of Rats from Optic Nerve Crush Invest Ophthalmol Vis Sci 2017 58 4877 88 10.1167/iovs.17-22179 28973334 Inada T Sato H Hayashi Y Hitomi S Furukawa A Ando M et al. Rapamycin Accelerates Axon Regeneration Through Schwann Cell-mediated Autophagy Following Inferior Alveolar Nerve Transection in Rats Neuroscience 2021 468 43 52 10.1016/j.neuroscience.2021.05.033 34102263 Li N Wang F Zhang Q Jin M Lu Y Chen S et al. Rapamycin mediates mTOR signaling in reactive astrocytes and reduces retinal ganglion cell loss Exp Eye Res 2018 176 10 9 10.1016/j.exer.2018.06.014 29928901 Xu L Zhang C Jiang N He D Bai Y Xin Y Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis J Cell Biochem 2019 120 5160 8 10.1002/jcb.27792 30320900 Lisi L Navarra P Cirocchi R Sharp A Stigliano E Feinstein DL et al. Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis J Neuroimmunol 2012 243 43 51 10.1016/j.jneuroim.2011.12.018 22264993 Feng X Hou H Zou Y Guo L Defective autophagy is associated with neuronal injury in a mouse model of multiple sclerosis Bosn J Basic Med Sci 2017 17 95 103 10.17305/bjbms.2017.1696 28086065 PMC5474114 Hou H Cao R Quan M Sun Y Sun H Zhang J et al. Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways J Neuroimmunol 2018 324 26 34 10.1016/j.jneuroim.2018.08.012 30205205 Li Z Nie L Chen L Sun Y Guo L Rapamycin alleviates inflammation by up-regulating TGF-β/Smad signaling in a mouse model of autoimmune encephalomyelitis Nan Fang Yi Ke Da Xue Xue Bao 2019 39 35 42. Chinese 10.12122/j.issn.1673-4254.2019.01.06 30692064 PMC6765580 Li Z Nie L Chen L Sun Y Li G Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg/Th17 in a mouse model Neurosci Lett 2019 705 39 45 10.1016/j.neulet.2019.04.035 31004709 Hou H Miao J Cao R Han M Sun Y Liu X et al. Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway Neurochem Res 2017 42 2831 40 10.1007/s11064-017-2296-7 28600752 Li Z Chen L Niu X Liu J Ping M Li R et al. Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE) J Neuroimmunol 2012 250 9 17 10.1016/j.jneuroim.2012.05.008 22673299 Esposito M Ruffini F Bellone M Gagliani N Battaglia M Martino G et al. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation J Neuroimmunol 2010 220 52 63 10.1016/j.jneuroim.2010.01.001 20149931 Donia M Mangano K Amoroso A Mazzarino MC Imbesi R Castrogiovanni P et al. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells J Autoimmun 2009 33 135 40 10.1016/j.jaut.2009.06.003 19625166 Borim PA Mimura LAN Zorzella-Pezavento SFG Polonio CM Peron JPS Sartori A et al. Effect of Rapamycin on MOG-Reactive Immune Cells and Lipopolysaccharide-Activated Microglia: An In Vitro Approach for Screening New Therapies for Multiple Sclerosis J Interferon Cytokine Res 2022 42 153 60 10.1089/jir.2021.0206 35384725 Zhang G Yin L Luo Z Chen X He Y Yu X et al. Effects and potential mechanisms of rapamycin on MPTP-induced acute Parkinson’s disease in mice Ann Palliat Med 2021 10 2889 97 10.21037/apm-20-1096 33549024 Currim F Singh J Shinde A Gohel D Roy M Singh K et al. Exosome Release Is Modulated by the Mitochondrial-Lysosomal Crosstalk in Parkinson’s Disease Stress Conditions Mol Neurobiol 2021 58 1819 33 10.1007/s12035-020-02243-3 33404982 Pupyshev AB Tenditnik MV Ovsyukova MV Akopyan AA Dubrovina NI Tikhonova MA Restoration of Parkinson’s Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson’s Disease in Mice Bull Exp Biol Med 2021 171 425 30 10.1007/s10517-021-05242-z 34542745 Guo Q Wang B Wang X Smith WW Zhu Y Liu Z Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models Cells 2021 10 1850 10.3390/cells10081850 34440619 PMC8394528 Srivastava IN Shperdheja J Baybis M Ferguson T Crino PB mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy Neurobiol Dis 2016 85 144 54 10.1016/j.nbd.2015.10.001 26459113 Abdulrahman BA Tahir W Doh-Ura K Gilch S Schatzl HM Combining autophagy stimulators and cellulose ethers for therapy against prion disease Prion 2019 13 185 96 10.1080/19336896.2019.1670928 31578923 PMC6779372 Cortes CJ Qin K Cook J Solanki A Mastrianni JA Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Sträussler-Scheinker disease J Neurosci 2012 32 12396 405 10.1523/JNEUROSCI.6189-11.2012 22956830 PMC3752082 Ishibashi D Homma T Nakagaki T Fuse T Sano K Takatsuki H et al. Strain-Dependent Effect of Macroautophagy on Abnormally Folded Prion Protein Degradation in Infected Neuronal Cells PLoS One 2015 10 e0137958 10.1371/journal.pone.0137958 26368533 PMC4569470 Wang H Fu J Xu X Yang Z Zhang T Rapamycin Activates Mitophagy and Alleviates Cognitive and Synaptic Plasticity Deficits in a Mouse Model of Alzheimer’s Disease J Gerontol A Biol Sci Med Sci 2021 76 1707 13 10.1093/gerona/glab142 34003967 Pupyshev AB Belichenko VM Tenditnik MV Bashirzade AA Dubrovina NI Ovsyukova MV et al. Combined induction of mTOR-dependent and mTOR-independent pathways of autophagy activation as an experimental therapy for Alzheimer’s disease-like pathology in a mouse model Pharmacol Biochem Behav 2022 217 173406 10.1016/j.pbb.2022.173406 35609863 Van Skike CE Hussong SA Hernandez SF Banh AQ DeRosa N Galvan V mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer’s Disease J Neurosci 2021 41 4305 20 10.1523/JNEUROSCI.2144-20.2021 33888602 PMC8143195 Kakoty V C SK Yang CH Kumari S Dubey SK Taliyan R Neuroprotective Effect of Lentivirus-Mediated FGF21 Gene Delivery in Experimental Alzheimer’s Disease is Augmented when Concerted with Rapamycin Mol Neurobiol 2022 59 2659 77 10.1007/s12035-022-02741-6 35142986 Lai C Chen Z Ding Y Chen Q Su S Liu H et al. Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways Front Immunol 2022 13 782434 10.3389/fimmu.2022.782434 35197970 PMC8858937 Zheng G Wang L Li X Niu X Xu G Lv P Rapamycin alleviates cognitive impairment in murine vascular dementia: The enhancement of mitophagy by PI3K/AKT/mTOR axis Tissue Cell 2021 69 101481 10.1016/j.tice.2020.101481 33383488 Ding Y Liu H Cen M Tao Y Lai C Tang Z Rapamycin Ameliorates Cognitive Impairments and Alzheimer’s Disease-Like Pathology with Restoring Mitochondrial Abnormality in the Hippocampus of Streptozotocin-Induced Diabetic Mice Neurochem Res 2021 46 265 75 10.1007/s11064-020-03160-6 33140268 Jiang T Zhang W Wang Y Zhang T Wang H Yang Z Rapamycin Pretreatment Attenuates High Glucose-induced Alteration of Synaptic Transmission in Hippocampal Dentate Gyrus Neurons Neuroscience 2022 490 182 92 10.1016/j.neuroscience.2022.03.012 35306144 Ravikumar B Vacher C Berger Z Davies JE Luo S Oroz LG et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease Nat Genet 2004 36 585 95 10.1038/ng1362 15146184 King MA Hands S Hafiz F Mizushima N Tolkovsky AM Wyttenbach A Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis Mol Pharmacol 2008 73 1052 63 10.1124/mol.107.043398 18199701 Pereira GJ Tressoldi N Hirata H Bincoletto C Smaili SS Autophagy as a neuroprotective mechanism against 3-nitropropionic acid-induced murine astrocyte cell death Neurochem Res 2013 38 2418 26 10.1007/s11064-013-1154-5 24085658 Sarkar S Davies JE Huang Z Tunnacliffe A Rubinsztein DC Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and α-synuclein J Biol Chem 2007 282 5641 52 10.1074/jbc.M609532200 17182613 Chen LL Wu JC Wang LH Wang J Qin ZH Difiglia M et al. Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes Acta Pharmacol Sin 2012 33 385 92 10.1038/aps.2011.162 22266730 PMC4077128 Sarkar S Krishna G Imarisio S Saiki S O’Kane CJ Rubinsztein DC A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin Hum Mol Genet 2008 17 170 8 10.1093/hmg/ddm294 17921520 Kolosova NG Muraleva NA Zhdankina AA Stefanova NA Fursova AZ Blagosklonny MV Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats Am J Pathol 2012 181 472 7 10.1016/j.ajpath.2012.04.018 22683466 Kitaoka Y Munemasa Y Kojima K Hirano A Ueno S Takagi H Axonal protection by Nmnat3 overexpression with involvement of autophagy in optic nerve degeneration Cell Death Dis 2013 4 e860 10.1038/cddis.2013.391 24136224 PMC3920931 Russo R Varano GP Adornetto A Nazio F Tettamanti G Girardello R et al. Rapamycin and fasting sustain autophagy response activated by ischemia/reperfusion injury and promote retinal ganglion cell survival Cell Death Dis 2018 9 981 10.1038/s41419-018-1044-5 30250019 PMC6155349 Xu C Zhang H Liu C Zhu Y Wang X Gao W et al. Rapamycin inhibits Erk1/2-mediated neuronal apoptosis caused by cadmium Oncotarget 2015 6 21452 67 10.18632/oncotarget.4087 26046303 PMC4673278 Wang T Yuan Y Zou H Yang J Zhao S Ma Y et al. The ER stress regulator Bip mediates cadmium-induced autophagy and neuronal senescence Sci Rep 2016 6 38091 10.1038/srep38091 27905509 PMC5131476 Xu C Liu C Liu L Zhang R Zhang H Chen S et al. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways Neuropharmacology 2015 97 35 45 10.1016/j.neuropharm.2015.05.008 26002629 PMC4537379 Xu C Wang X Zhu Y Dong X Liu C Zhang H et al. Rapamycin ameliorates cadmium-induced activation of MAPK pathway and neuronal apoptosis by preventing mitochondrial ROS inactivation of PP2A Neuropharmacology 2016 105 270 84 10.1016/j.neuropharm.2016.01.030 26805420 PMC4873321 Guo S Xu N Chen P Liu Y Qi X Liu S et al. Rapamycin Protects Spiral Ganglion Neurons from Gentamicin-Induced Degeneration In Vitro J Assoc Res Otolaryngol 2019 20 475 87 10.1007/s10162-019-00717-3 31236744 PMC6797692 Caccamo A Magrì A Medina DX Wisely EV López-Aranda MF Silva AJ et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer’s disease and other tauopathies Aging Cell 2013 12 370 80 10.1111/acel.12057 23425014 PMC3655115 Ozcelik S Fraser G Castets P Schaeffer V Skachokova Z Breu K et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice PLoS One 2013 8 e62459 10.1371/journal.pone.0062459 23667480 PMC3646815 Cullen V Sardi SP Ng J Xu YH Sun Y Tomlinson JJ et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing Ann Neurol 2011 69 940 53 10.1002/ana.22400 21472771 Hoffmann AC Minakaki G Menges S Salvi R Savitskiy S Kazman A et al. Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose Sci Rep 2019 9 544 10.1038/s41598-018-35811-8 30679445 PMC6345801 Rockenstein E Ostroff G Dikengil F Rus F Mante M Florio J et al. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies J Neurosci 2018 38 1000 14 10.1523/JNEUROSCI.1170-17.2017 29246926 PMC5783958 Jing F Yang F Cui F Chen Z Ling L Huang X Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis Biosci Rep 2017 37 BSR20170767 10.1042/BSR20170767 28655853 PMC5518538 Gao X Wen Y Wang Z Wang G Guo J Yu L et al. Rapamycin alleviates the symptoms of experimental autoimmune myasthenia gravis rats by down-regulating Th17 cell/regulatory T cell ratio Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2021 37 24 30. Chinese 33441225 Uberti VH de Freitas BS Molz P Bromberg E Schröder N Iron Overload Impairs Autophagy: Effects of Rapamycin in Ameliorating Iron-Related Memory Deficits Mol Neurobiol 2020 57 1044 54 10.1007/s12035-019-01794-4 31664701 Zhang CQ Yi S Chen BB Cui PP Wang Y Li YZ mTOR/NF-κB signaling pathway protects hippocampal neurons from injury induced by intermittent hypoxia in rats Int J Neurosci 2021 131 994 1003 10.1080/00207454.2020.1766460 32378972 Sabran-Cohen T Bright U Mizrachi Zer-Aviv T Akirav I Rapamycin prevents the long-term impairing effects of adolescence Δ-9-tetrahydrocannabinol on memory and plasticity in male rats Eur J Neurosci 2021 54 6104 22 10.1111/ejn.15425 34405459 Chen X Gao F Lin C Chen A Deng J Chen P et al. mTOR-mediated autophagy in the hippocampus is involved in perioperative neurocognitive disorders in diabetic rats CNS Neurosci Ther 2022 28 540 53 10.1111/cns.13762 34784444 PMC8928925 Chen G Ke Z Xu M Liao M Wang X Qi Y et al. Autophagy is a protective response to ethanol neurotoxicity Autophagy 2012 8 1577 89 10.4161/auto.21376 22874567 PMC3494588 Yang N Liu X Niu X Wang X Jiang R Yuan N et al. Activation of Autophagy Ameliorates Age-Related Neurogenesis Decline and Neurodysfunction in Adult Mice Stem Cell Rev Rep 2022 18 626 41 10.1007/s12015-021-10265-0 34546510 Ni L Wei Y Pan J Li X Xu B Deng Y et al. The effects of mTOR or Vps34-mediated autophagy on methylmercury-induced neuronal apoptosis in rat cerebral cortex Food Chem Toxicol 2021 155 112386 10.1016/j.fct.2021.112386 34242720 Caccamo A Majumder S Deng JJ Bai Y Thornton FB Oddo S Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability J Biol Chem 2009 284 27416 24 10.1074/jbc.M109.031278 19651785 PMC2785671 Chennampally P Sayed-Zahid A Soundararajan P Sharp J Cox GA Collins SD et al. A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin Sci Rep 2021 11 18168 10.1038/s41598-021-97405-1 34518579 PMC8438029 Tsai PT Rudolph S Guo C Ellegood J Gibson JM Schaeffer SM et al. Sensitive Periods for Cerebellar-Mediated Autistic-like Behaviors Cell Rep 2018 25 357 67.e4 10.1016/j.celrep.2018.09.039 30304677 PMC6226056 Kotajima-Murakami H Kobayashi T Kashii H Sato A Hagino Y Tanaka M et al. Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero Mol Brain 2019 12 3 10.1186/s13041-018-0423-2 30621732 PMC6325753 McMahon JJ Yu W Yang J Feng H Helm M McMahon E et al. Seizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice Neurobiol Dis 2015 73 296 306 10.1016/j.nbd.2014.10.004 25315683 PMC4394017 Burket JA Benson AD Tang AH Deutsch SI Rapamycin improves sociability in the BTBR T+Itpr3tf/J mouse model of autism spectrum disorders Brain Res Bull 2014 100 70 5 10.1016/j.brainresbull.2013.11.005 24295733 PMC5581959 Xing X Zhang J Wu K Cao B Li X Jiang F et al. Suppression of Akt-mTOR pathway rescued the social behavior in Cntnap2-deficient mice Sci Rep 2019 9 3041 10.1038/s41598-019-39434-5 30816216 PMC6395585 Wu J de Theije CG da Silva SL van der Horst H Reinders MT Broersen LM et al. mTOR plays an important role in cow’s milk allergy-associated behavioral and immunological deficits Neuropharmacology 2015 97 220 32 10.1016/j.neuropharm.2015.04.035 26027949 Xie J Han Q Wei Z Wang Y Wang S Chen M Phenanthrene induces autism-like behavior by promoting oxidative stress and mTOR pathway activation Toxicology 2021 461 152910 10.1016/j.tox.2021.152910 34453960 Iezzi D Curti L Ranieri G Gerace E Costa A Ilari A et al. Acute rapamycin rescues the hyperexcitable phenotype of accumbal medium spiny neurons in the valproic acid rat model of autism spectrum disorder Pharmacol Res 2022 183 106401 10.1016/j.phrs.2022.106401 35987482 Amegandjin CA Choudhury M Jadhav V Carriço JN Quintal A Berryer M et al. Sensitive period for rescuing parvalbumin interneurons connectivity and social behavior deficits caused by TSC1 loss Nat Commun 2021 12 3653 10.1038/s41467-021-23939-7 34135323 PMC8209106 Del Grosso A Angella L Tonazzini I Moscardini A Giordano N Caleo M et al. Dysregulated autophagy as a new aspect of the molecular pathogenesis of Krabbe disease Neurobiol Dis 2019 129 195 207 10.1016/j.nbd.2019.05.011 31108173 Di Domenico F Tramutola A Barone E Lanzillotta C Defever O Arena A et al. Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome Redox Biol 2019 23 101162 10.1016/j.redox.2019.101162 30876754 PMC6859577 Andrade-Talavera Y Benito I Casañas JJ Rodríguez-Moreno A Montesinos ML Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down’s syndrome Neurobiol Dis 2015 82 516 25 10.1016/j.nbd.2015.09.005 26388397 Troca-Marín JA Alves-Sampaio A Montesinos ML An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down’s syndrome J Neurosci 2011 31 9445 55 10.1523/JNEUROSCI.0011-11.2011 21715609 PMC6623175 Urbano-Gámez JD Casañas JJ Benito I Montesinos ML Prenatal treatment with rapamycin restores enhanced hippocampal mGluR-LTD and mushroom spine size in a Down’s syndrome mouse model Mol Brain 2021 14 84 10.1186/s13041-021-00795-6 34034796 PMC8152312 Reijnders MRF Kousi M van Woerden GM Klein M Bralten J Mancini GMS et al. Variation in a range of mTOR-related genes associates with intracranial volume and intellectual disability Nat Commun 2017 8 1052 10.1038/s41467-017-00933-6 29051493 PMC5648772 Lopatynska-Mazurek M Antolak A Grochecki P Gibula-Tarlowska E Bodzon-Kulakowska A Listos J et al. Rapamycin Improves Spatial Learning Deficits, Vulnerability to Alcohol Addiction and Altered Expression of the GluN2B Subunit of the NMDA Receptor in Adult Rats Exposed to Ethanol during the Neonatal Period Biomolecules 2021 11 650 10.3390/biom11050650 33924998 PMC8147055 Lopatynska-Mazurek M Pankowska A Gibula-Tarlowska E Pietura R Kotlinska JH Rapamycin Improves Recognition Memory and Normalizes Amino-Acids and Amines Levels in the Hippocampal Dentate Gyrus in Adult Rats Exposed to Ethanol during the Neonatal Period Biomolecules 2021 11 362 10.3390/biom11030362 33673489 PMC7997340 Lopatynska-Mazurek M Komsta L Gibula-Tarlowska E Kotlinska JH Aversive Learning Deficits and Depressive-Like Behaviors Are Accompanied by an Increase in Oxidative Stress in a Rat Model of Fetal Alcohol Spectrum Disorders: The Protective Effect of Rapamycin Int J Mol Sci 2021 22 7083 10.3390/ijms22137083 34209274 PMC8268794 Chi OZ Wu CC Liu X Rah KH Jacinto E Weiss HR Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis Neuromolecular Med 2015 17 305 13 10.1007/s12017-015-8359-5 26048361 PMC4888058 TTang G Gudsnuk K Kuo SH Cotrina ML Rosoklija G Sosunov A et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits Neuron 2014 83 1131 43 10.1016/j.neuron.2014.07.040 25155956 PMC4159743 Tsai PT Hull C Chu Y Greene-Colozzi E Sadowski AR Leech JM et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice Nature 2012 488 647 51 10.1038/nature11310 22763451 PMC3615424 Sato A Kasai S Kobayashi T Takamatsu Y Hino O Ikeda K et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex Nat Commun 2012 3 1292 10.1038/ncomms2295 23250422 PMC3535343 Carson RP Van Nielen DL Winzenburger PA Ess KC Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin Neurobiol Dis 2012 45 369 80 10.1016/j.nbd.2011.08.024 21907282 PMC3225598 Meikle L Pollizzi K Egnor A Kramvis I Lane H Sahin M et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function J Neurosci 2008 28 5422 32 10.1523/JNEUROSCI.0955-08.2008 18495876 PMC2633923 Sundberg M Tochitsky I Buchholz DE Winden K Kujala V Kapur K et al. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin Mol Psychiatry 2018 23 2167 83 10.1038/s41380-018-0018-4 29449635 PMC6093816 Karalis V Caval-Holme F Bateup HS Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex Nat Commun 2022 13 4665 10.1038/s41467-022-31961-6 35945201 PMC9363483 Koike-Kumagai M Fujimoto M Wataya-Kaneda M Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice Neuropharmacology 2022 218 109203 10.1016/j.neuropharm.2022.109203 35931213 Way SW Rozas NS Wu HC McKenna J 3rd Reith RM Hashmi SS et al. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex Hum Mol Genet 2012 21 3226 36 10.1093/hmg/dds156 22532572 PMC3384384 Martin P Wagh V Reis SA Erdin S Beauchamp RL Shaikh G et al. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling Mol Autism 2020 11 2 10.1186/s13229-019-0311-3 31921404 PMC6945400 Ehninger D Han S Shilyansky C Zhou Y Li W Kwiatkowski DJ et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis Nat Med 2008 14 843 8 10.1038/nm1788 18568033 PMC2664098 Cambiaghi M Cursi M Magri L Castoldi V Comi G Minicucci F et al. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex Neuropharmacology 2013 67 1 7 10.1016/j.neuropharm.2012.11.003 23159330 Linda K Lewerissa EI Verboven AHA Gabriele M Frega M Klein Gunnewiek TM et al. Imbalanced autophagy causes synaptic deficits in a human model for neurodevelopmental disorders Autophagy 2022 18 423 42 10.1080/15548627.2021.1936777 34286667 PMC8942553 Zhong S Zhao Z Xie W Cai Y Zhang Y Ding J et al. GABAergic Interneuron and Neurotransmission Are mTOR-Dependently Disturbed in Experimental Focal Cortical Dysplasia Mol Neurobiol 2021 58 156 69 10.1007/s12035-020-02086-y 32909150 Crutcher E Pal R Naini F Zhang P Laugsch M Kim J et al. mTOR and autophagy pathways are dysregulated in murine and human models of Schaaf-Yang syndrome Sci Rep 2019 9 15935 10.1038/s41598-019-52287-2 31685878 PMC6828689 Gordon EB Hart GT Tran TM Waisberg M Akkaya M Skinner J et al. Inhibiting the Mammalian target of rapamycin blocks the development of experimental cerebral malaria mBio 2015 6 e00725 10.1128/mBio.00725-15 26037126 PMC4453009 Mejia P Treviño-Villarreal JH Reynolds JS De Niz M Thompson A Marti M et al. A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration Malar J 2017 16 455 10.1186/s12936-017-2092-5 29121917 PMC5679345 Mejia P Treviño-Villarreal JH Hine C Harputlugil E Lang S Calay E et al. Dietary restriction protects against experimental cerebral malaria via leptin modulation and T-cell mTORC1 suppression Nat Commun 2015 6 6050 10.1038/ncomms7050 25636003 PMC4313624 Hu J Chen X Cheng J Kong F Xia H Wu J Mammalian target of rapamycin signaling pathway is involved in synaptic plasticity of the spinal dorsal horn and neuropathic pain in rats by regulating autophagy Neuroreport 2021 32 925 35 10.1097/WNR.0000000000001684 34145195 Liu F Wu M Kai J Dong J Zhang B Liu L et al. Effectiveness of low dose of rapamycin in preventing seizure-induced anxiety-like behaviour, cognitive impairment, and defects in neurogenesis in developing rats Int J Neurosci 2020 130 9 18 10.1080/00207454.2018.1486827 29883228 Blundell J Kouser M Powell CM Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation Neurobiol Learn Mem 2008 90 28 35 10.1016/j.nlm.2007.12.004 18316213 PMC2497420 Fifield K Hebert M Angel R Adamec R Blundell J Inhibition of mTOR kinase via rapamycin blocks persistent predator stress-induced hyperarousal Behav Brain Res 2013 256 457 63 10.1016/j.bbr.2013.08.047 24001755 Levin N Kritman M Maroun M Akirav I Differential roles of the infralimbic and prelimbic areas of the prefrontal cortex in reconsolidation of a traumatic memory Eur Neuropsychopharmacol 2017 27 900 12 10.1016/j.euroneuro.2017.06.007 28647452 Li Y Cheng Y Zhou Y Du H Zhang C Zhao Z et al. High fat diet-induced obesity leads to depressive and anxiety-like behaviors in mice via AMPK/mTOR-mediated autophagy Exp Neurol 2022 348 113949 10.1016/j.expneurol.2021.113949 34902357 Wang S Zhou SL Min FY Ma JJ Shi XJ Bereczki E et al. mTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice Metab Brain Dis 2014 29 729 36 10.1007/s11011-014-9528-1 24682776 Sun Q Wei LL Zhang M Li TX Yang C Deng SP et al. Rapamycin inhibits activation of AMPK-mTOR signaling pathway-induced Alzheimer’s disease lesion in hippocampus of rats with type 2 diabetes mellitus Int J Neurosci 2019 129 179 88 10.1080/00207454.2018.1491571 29962282 Xu T Liu J Li XR Yu Y Luo X Zheng X et al. The mTOR/NF-κB Pathway Mediates Neuroinflammation and Synaptic Plasticity in Diabetic Encephalopathy Mol Neurobiol 2021 58 3848 62 10.1007/s12035-021-02390-1 33860440 Gao Y Peng S Wen Q Zheng C Lin J Tan Y et al. The mammalian target of rapamycin pathway in the basolateral amygdala is critical for nicotine-induced behavioural sensitization Int J Neuropsychopharmacol 2014 17 1881 94 10.1017/S1461145714000650 24916432 Zhou Y Liang Y Kreek MJ mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice Pharmacol Biochem Behav 2020 195 172954 10.1016/j.pbb.2020.172954 32470351 PMC7442164 Barak S Liu F Ben Hamida S Yowell QV Neasta J Kharazia V et al. Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse Nat Neurosci 2013 16 1111 7 10.1038/nn.3439 23792945 PMC3725202 Canivet C Menasria R Rhéaume C Piret J Boivin G Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone Antiviral Res 2015 123 105 13 10.1016/j.antiviral.2015.09.007 26374952 Kara NZ Flaisher-Grinberg S Anderson GW Agam G Einat H Mood-stabilizing effects of rapamycin and its analog temsirolimus: relevance to autophagy Behav Pharmacol 2018 29 379 84 10.1097/FBP.0000000000000334 28777104 Akman O Briggs SW Mowrey WB Moshé SL Galanopoulou AS Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions Epilepsia 2021 62 1985 99 10.1111/epi.16975 34212374 PMC8654607 Ishida S Zhao D Sawada Y Hiraoka Y Mashimo T Tanaka K Dorsal telencephalon-specific Nprl2- and Nprl3-knockout mice: novel mouse models for GATORopathy Hum Mol Genet 2022 31 1519 30 10.1093/hmg/ddab337 34965576 PMC9071434 Xie P Zhu S Zhou H Fang R Zhuang J Wen J et al. Rapamycin Plays an Anti-Epileptic Role by Restoring Blood-Brain Barrier Dysfunction, Balancing T Cell Subsets and Inhibiting Neuronal Apoptosis Discov Med 2023 35 1043 51 38058069 Liu L Liu Z Zeng C Xu Y He L Fang Q et al. Dynorphin/KOR inhibits neuronal autophagy by activating mTOR signaling pathway to prevent acute seizure epilepsy Cell Biol Int 2022 46 1814 24 10.1002/cbin.11874 35989483 Aghaie F Moradifar F Hosseini A Rapamycin attenuates depression and anxiety-like behaviors through modulation of the NLRP3 pathway in pentylenetetrazole-kindled male Wistar rats Fundam Clin Pharmacol 2021 35 1045 54 10.1111/fcp.12689 33930202 Ding N Zhao K Lan Y Li Z Lv X Su J et al. Induction of Atypical Autophagy by Porcine Hemagglutinating Encephalomyelitis Virus Contributes to Viral Replication Front Cell Infect Microbiol 2017 7 56 10.3389/fcimb.2017.00056 28293544 PMC5328988 Li GY Fan B Jiao YY Rapamycin attenuates visible light-induced injury in retinal photoreceptor cells via inhibiting endoplasmic reticulum stress Brain Res 2014 1563 1 12 10.1016/j.brainres.2014.02.020 24607296 Nalbandian A Llewellyn KJ Nguyen C Yazdi PG Kimonis VE Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy PLoS One 2015 10 e0122888 10.1371/journal.pone.0122888 25884947 PMC4401571 Hayashi I Aoki Y Ushikubo H Asano D Mori A Sakamoto K et al. Protective effects of PF-4708671 against N-methyl-d-aspartic acid-induced retinal damage in rats Fundam Clin Pharmacol 2016 30 529 36 10.1111/fcp.12216 27371338 Ichikawa A Nakahara T Kurauchi Y Mori A Sakamoto K Ishii K Rapamycin prevents N-methyl-D-aspartate-induced retinal damage through an ERK-dependent mechanism in rats J Neurosci Res 2014 92 692 702 10.1002/jnr.23358 24510654 Aoki Y Nakahara T Asano D Ushikubo H Mori A Sakamoto K et al. Preventive effects of rapamycin on inflammation and capillary degeneration in a rat model of NMDA-induced retinal injury Biol Pharm Bull 2015 38 321 4 10.1248/bpb.b14-00631 25747992 Ying H Turturro S Nguyen T Shen X Zelkha R Johnson EC et al. Induction of autophagy in rats upon overexpression of wild-type and mutant optineurin gene BMC Cell Biol 2015 16 14 10.1186/s12860-015-0060-x 25943884 PMC4429416 Foerster P Daclin M Asm S Faucourt M Boletta A Genovesio A et al. mTORC1 signaling and primary cilia are required for brain ventricle morphogenesis Development 2017 144 201 10 10.1242/dev.138271 27993979 PMC5394754 Metaxakis A Tain LS Grönke S Hendrich O Hinze Y Birras U et al. Lowered insulin signalling ameliorates age-related sleep fragmentation in Drosophila PLoS Biol 2014 12 e1001824 10.1371/journal.pbio.1001824 24690889 PMC3972082 Cleary C Linde JA Hiscock KM Hadas I Belmaker RH Agam G et al. Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders Brain Res Bull 2008 76 469 73 10.1016/j.brainresbull.2008.03.005 18534253 James MH Quinn RK Ong LK Levi EM Charnley JL Smith DW et al. mTORC1 inhibition in the nucleus accumbens ‘protects’ against the expression of drug seeking and ‘relapse’ and is associated with reductions in GluA1 AMPAR and CAMKIIα levels Neuropsychopharmacology 2014 39 1694 702 10.1038/npp.2014.16 24469593 PMC4023142 James MH Quinn RK Ong LK Levi EM Smith DW Dickson PW et al. Rapamycin reduces motivated responding for cocaine and alters GluA1 expression in the ventral but not dorsal striatum Eur J Pharmacol 2016 784 147 54 10.1016/j.ejphar.2016.05.013 27181066 Bailey J Ma D Szumlinski KK Rapamycin attenuates the expression of cocaine-induced place preference and behavioral sensitization Addict Biol 2012 17 248 58 10.1111/j.1369-1600.2010.00311.x 21392180 PMC3500570 Towner RA Gulej R Zalles M Saunders D Smith N Lerner M et al. Rapamycin restores brain vasculature, metabolism, and blood-brain barrier in an inflammaging model Geroscience 2021 43 563 78 10.1007/s11357-021-00363-9 33846885 PMC8110648 Felici R Buonvicino D Muzzi M Cavone L Guasti D Lapucci A et al. Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses Neuropharmacology 2017 117 74 84 10.1016/j.neuropharm.2017.01.039 28161373 Kim SG Lee S Kim Y Park J Woo D Kim D et al. Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons Nat Commun 2021 12 2695 10.1038/s41467-021-22908-4 33976205 PMC8113471 Wen J Xu J Mathena RP Choi JH Mintz CD Early Isoflurane Exposure Impairs Synaptic Development in Fmr1 KO Mice via the mTOR Pathway Neurochem Res 2021 46 1577 88 10.1007/s11064-021-03301-5 33791908 Tian J Wang Z Ren Y Jiang Y Zhao Y Li M et al. Rapamycin Attenuates Anxiety and Depressive Behavior Induced by Helicobacter pylori in Association with Reduced Circulating Levels of Ghrelin Neural Plast 2022 2022 2847672 10.1155/2022/2847672 35677839 PMC9170403 Zhao Y Zhao W Han Y Inhibition of mTORC2 improves brain injury in epileptic rats by promoting chaperone-mediated autophagy Epilepsy Res 2023 193 107161 10.1016/j.eplepsyres.2023.107161 37163909 Liu H Li F Li X Wu Q Dai C Rapamycin ameliorates age-related hearing loss in C57BL/6J mice by enhancing autophagy in the SGNs Neurosci Lett 2022 772 136493 10.1016/j.neulet.2022.136493 35114332 Pucha KA Ma TC York W Kang UJ Kaufmann H Kapogiannis D et al. Neuron-derived extracellular vesicles to examine brain mTOR target engagement with sirolimus in patients with multiple system atrophy Parkinsonism Relat Disord 2023 115 105821 10.1016/j.parkreldis.2023.105821 37643509 PMC10592064 Dusing M LaSarge CL White A Jerow LG Gross C Danzer SC Neurovascular Development in Pten and Tsc2 Mouse Mutants eNeuro 2023 10 ENEURO.0340 22.2023 10.1523/ENEURO.0340-22.2023 36759189 PMC9953070 Liu W Guo J Mu J Tian L Zhou D Rapamycin Protects Sepsis-Induced Cognitive Impairment in Mouse Hippocampus by Enhancing Autophagy Cell Mol Neurobiol 2017 37 1195 205 10.1007/s10571-016-0449-x 27904994 PMC11482117 Parker WE Orlova KA Parker WH Birnbaum JF Krymskaya VP Goncharov DA et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder Sci Transl Med 2013 5 182ra53 10.1126/scitranslmed.3005271 23616120 PMC3720125 Kato M Kada A Shiraishi H Tohyama J Nakagawa E Takahashi Y et al. Sirolimus for epileptic seizures associated with focal cortical dysplasia type II Ann Clin Transl Neurol 2022 9 181 92 10.1002/acn3.51505 35040598 PMC8862414 Zhang J Xu X Zhou D Li H You W Wang Z et al. Possible Role of Raf-1 Kinase in the Development of Cerebral Vasospasm and Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats Mol Neurobiol 2015 52 1527 39 10.1007/s12035-014-8939-7 25367879 Hsieh CH Lin YJ Chen WL Huang YC Chang CW Cheng FC et al. HIF-1α triggers long-lasting glutamate excitotoxicity via system xc- in cerebral ischaemia-reperfusion J Pathol 2017 241 337 49 10.1002/path.4838 27801527 Wang T Li B Wang Z Wang X Xia Z Ning G et al. Sorafenib promotes sensory conduction function recovery via miR-142-3p/AC9/cAMP axis post dorsal column injury Neuropharmacology 2019 148 347 57 10.1016/j.neuropharm.2019.01.031 30710569 Echeverria V Burgess S Gamble-George J Zeitlin R Lin X Cao C et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice Neuroscience 2009 162 1220 31 10.1016/j.neuroscience.2009.05.019 19447162 Kim J Park JH Park SK Hoe HS Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice Front Immunol 2021 12 684344 10.3389/fimmu.2021.684344 34122447 PMC8190398 Liu Z Hamamichi S Lee BD Yang D Ray A Caldwell GA et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson’s disease models Hum Mol Genet 2011 20 3933 42 10.1093/hmg/ddr312 21768216 PMC3177653 Moawad EY Induction of multiple sclerosis and response to tyrosine kinase inhibitors Indian J Clin Biochem 2014 29 491 5 10.1007/s12291-013-0387-z 25298631 PMC4175700 Crespo O Kang SC Daneman R Lindstrom TM Ho PP Sobel RA et al. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis J Clin Immunol 2011 31 1010 20 10.1007/s10875-011-9579-6 21847523 PMC3225802 Martina BEE Smreczak M Orlowska A Marzec A Trebas P Roose JM et al. Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus Vaccine 2019 37 4736 42 10.1016/j.vaccine.2018.05.065 29843998 Brahms A Mudhasani R Pinkham C Kota K Nasar F Zamani R et al. Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway J Virol 2017 91 e00968 17 10.1128/JVI.00968-17 28794043 PMC5640838 Lundberg L Brahms A Hooper I Carey B Lin SC Dahal B et al. Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses Antiviral Res 2018 157 57 67 10.1016/j.antiviral.2018.07.005 29981794 Gao M Duan H Liu J Zhang H Wang X Zhu M et al. The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins Antiviral Res 2014 106 80 5 10.1016/j.antiviral.2014.03.009 24680956 Welsbie DS Ziogas NK Xu L Kim BJ Ge Y Patel AK et al. Targeted disruption of dual leucine zipper kinase and leucine zipper kinase promotes neuronal survival in a model of diffuse traumatic brain injury Mol Neurodegener 2019 14 44 10.1186/s13024-019-0345-1 31775817 PMC6882250 Benini R Roth R Khoja Z Avoli M Wintermark P Does angiogenesis play a role in the establishment of mesial temporal lobe epilepsy? Int J Dev Neurosci 2016 49 31 6 10.1016/j.ijdevneu.2016.01.001 26773167 PMC4878886 Lee JC Kim HY Lee S Shin J Kim HV Kim K et al. Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memory-Impairing Anti-Parallel Aβ Dimers Angew Chem Int Ed Engl 2020 59 11491 500 10.1002/anie.202002574 32233096 Grammas P Martinez J Sanchez A Yin X Riley J Gay D et al. A new paradigm for the treatment of Alzheimer’s disease: targeting vascular activation J Alzheimers Dis 2014 40 619 30 10.3233/JAD-2014-132057 24503617 Son SM Jung ES Shin HJ Byun J Mook-Jung I Aβ-induced formation of autophagosomes is mediated by RAGE-CaMKKβ-AMPK signaling Neurobiol Aging 2012 33 1006.e11 23 10.1016/j.neurobiolaging.2011.09.039 22048125 Zhao P Cheng P Wang J Zhu G Wang X Shenqi Yizhi prescription prevents AβO-induced memory impairment in mice by regulating the contractility of brain pericytes Phytomedicine 2024 129 155639 10.1016/j.phymed.2024.155639 38669966 Wrasidlo W Crews LA Tsigelny IF Stocking E Kouznetsova VL Price D et al. Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders Br J Pharmacol 2014 171 5757 73 10.1111/bph.12875 25117211 PMC4290715 Fields JA Metcalf J Overk C Adame A Spencer B Wrasidlo W et al. The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration J Neurovirol 2017 23 290 303 10.1007/s13365-016-0502-z 28105557 PMC5729903 Pu SY Xiao F Schor S Bekerman E Zanini F Barouch-Bentov R et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment Antiviral Res 2018 155 67 75 10.1016/j.antiviral.2018.05.001 29753658 PMC6064211 Luo J Zhang Y Wang Y Liu Q Chen L Zhang B et al. Rhabdovirus Infection Is Dependent on Serine/Threonine Kinase AP2-Associated Kinase 1 Life (Basel) 2020 10 170 10.3390/life10090170 32872567 PMC7554979 Hsueh HT Chou RT Rai U Kolodziejski P Liyanage W Pejavar J et al. Engineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats J Control Release 2023 362 371 80 10.1016/j.jconrel.2023.08.058 37657693 PMC10591956 Siracusa R Paterniti I Cordaro M Crupi R Bruschetta G Campolo M et al. Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson’s Disease Mol Neurobiol 2018 55 2403 19 10.1007/s12035-017-0496-4 28357809 Decressac M Björklund A mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats J Parkinsons Dis 2013 3 13 7 10.3233/JPD-120155 23938307 Jiang T Yu JT Zhu XC Zhang QQ Cao L Wang HF et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance Neuropharmacology 2014 85 121 30 10.1016/j.neuropharm.2014.05.032 24880087 Frederick C Ando K Leroy K Héraud C Suain V Buée L et al. Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice J Alzheimers Dis 2015 44 1145 56 10.3233/JAD-142097 25408212 Jiang T Yu JT Zhu XC Tan MS Wang HF Cao L et al. Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer’s disease Pharmacol Res 2014 81 54 63 10.1016/j.phrs.2014.02.008 24602800 Menzies FM Huebener J Renna M Bonin M Riess O Rubinsztein DC Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3 Brain 2010 133 93 104 10.1093/brain/awp292 20007218 PMC2801325 Saravia R Flores Á Plaza-Zabala A Busquets-Garcia A Pastor A de la Torre R et al. CB1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal Biol Psychiatry 2017 81 625 34 10.1016/j.biopsych.2016.07.007 27737762 Launay N Aguado C Fourcade S Ruiz M Grau L Riera J et al. Autophagy induction halts axonal degeneration in a mouse model of X-adrenoleukodystrophy Acta Neuropathol 2015 129 399 415 10.1007/s00401-014-1378-8 25549970 PMC4331612 Konoeda F Shichita T Yoshida H Sugiyama Y Muto G Hasegawa E et al. Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model Biochem Biophys Res Commun 2010 402 500 6 10.1016/j.bbrc.2010.10.058 20965150 Yang L Liu Y Wang Y Li J Liu N Azeliragon ameliorates Alzheimer’s disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway Clinics (Sao Paulo) 2021 76 e2348 10.6061/clinics/2021/e2348 33681944 PMC7920406 Zhou Y Leng X Luo S Su Z Luo X Guo H et al. Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance J Immunol Res 2016 2016 5021537 10.1155/2016/5021537 28070525 PMC5187469 Günaydın C Önger ME Avcı B Bozkurt A Terzi M Bilge SS Tofacitinib enhances remyelination and improves myelin integrity in cuprizone-induced mice Immunopharmacol Immunotoxicol 2021 43 790 8 10.1080/08923973.2021.1986063 34618622 Alshammari A Alharbi M Albekairi NA Albekairi TH Alharbi OO Yeapuri P et al. Protective Effect of CP690550 in MPTP-Induced Parkinson’s Like Behavioural, Biochemical and Histological Alterations in Mice Neurotox Res 2022 40 564 72 10.1007/s12640-022-00498-3 35366203 Figueroa-Romero C Monteagudo A Murdock BJ Famie JP Webber-Davis IF Piecuch CE et al. Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis Front Immunol 2022 13 773288 10.3389/fimmu.2022.773288 35197969 PMC8859451 Risner K Ahmed A Bakovic A Kortchak S Bhalla N Narayanan A Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection Viruses 2019 11 1151 10.3390/v11121151 31842327 PMC6950191 Ma H Wang C Han L Kong F Liu Z Zhang B et al. Tofacitinib Promotes Functional Recovery after Spinal Cord Injury by Regulating Microglial Polarization via JAK/STAT Signaling Pathway Int J Biol Sci 2023 19 4865 82 10.7150/ijbs.84564 37781508 PMC10539697 Zhou Y Chen L Zheng X Fang Q Qian Y Xu T et al. Microglia orchestrate synaptic and neuronal stripping: Implication in neuropsychiatric lupus J Cell Mol Med 2024 28 e18190 10.1111/jcmm.18190 38494844 PMC10945089 Huang Y Li Q Tian H Yao X Bakina O Zhang H et al. MEK inhibitor trametinib attenuates neuroinflammation and cognitive deficits following traumatic brain injury in mice Am J Transl Res 2020 12 6351 65 33194035 PMC7653601 Christensen ST Haanes KA Spray S Grell AS Warfvinge K Edvinsson L et al. Pre-clinical effects of highly potent MEK1/2 inhibitors on rat cerebral vasculature after organ culture and subarachnoid haemorrhage Clin Sci (Lond) 2019 133 1797 811 10.1042/CS20190636 31387935 Park ES Kim S Huang S Yoo JY Körbelin J Lee TJ et al. Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice Ann Neurol 2021 89 926 41 10.1002/ana.26059 33675084 Caldi Gomes L Hänzelmann S Hausmann F Khatri R Oller S Parvaz M et al. Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target Nat Commun 2024 15 4893 10.1038/s41467-024-49196-y 38849340 PMC11161513 Yue W Deng X Wang Z Jiang M Hu R Duan Y et al. Inhibition of the MEK/ERK pathway suppresses immune overactivation and mitigates TDP-43 toxicity in a Drosophila model of ALS Immun Ageing 2023 20 27 10.1186/s12979-023-00354-8 37340309 PMC10280928 Kim MY Kim MJ Lee C Lee J Kim SS Hong S et al. Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer’s disease Exp Mol Med 2023 55 2177 89 10.1038/s12276-023-01073-2 37779138 PMC10618442 Chun YS Kim MY Lee SY Kim MJ Hong TJ Jeon JK et al. MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer’s Disease Mol Psychiatry 2022 27 4770 80 10.1038/s41380-022-01713-5 35948663 PMC9734062 Yang Y Suo N Cui SH Wu X Ren XY Liu Y et al. Trametinib, an anti-tumor drug, promotes oligodendrocytes generation and myelin formation Acta Pharmacol Sin 2024 45 2527 39 10.1038/s41401-024-01313-9 38871922 Ballabh P Xu H Hu F Braun A Smith K Rivera A et al. Angiogenic inhibition reduces germinal matrix hemorrhage Nat Med 2007 13 477 85 10.1038/nm1558 17401377 Oliveira-Santos A Dagda M Wittmann J Smalley R Burkin DJ Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy Dis Model Mech 2023 16 dmm049916 10.1242/dmm.049916 37021539 PMC10184677 Wager TT Hou X Verhoest PR Villalobos A Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery ACS Chem Neurosci 2016 7 767 75 10.1021/acschemneuro.6b00029 26991242 Wager TT Hou X Verhoest PR Villalobos A Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem Neurosci 2010 1 435 49 10.1021/cn100008c 22778837 PMC3368654 Tsang JE Urner LM Kim G Chow K Baufeld L Faull K et al. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors ACS Med Chem Lett 2020 11 1799 809 10.1021/acsmedchemlett.9b00599 33062157 PMC7549123 van Hoppe S Rood JJM Buil L Wagenaar E Sparidans RW Beijnen JH et al. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability Mol Pharm 2018 15 5124 34 10.1021/acs.molpharmaceut.8b00702 30247919 Reich DS Arnold DL Vermersch P Bar-Or A Fox RJ Matta A et al. Tolebrutinib Phase 2b Study Group Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial Lancet Neurol 2021 20 729 38 10.1016/S1474-4422(21)00237-4 34418400 PMC8434816 Ren L Moreno D Baer BR Barbour P Bettendorf T Bouhana K Brown K et al. Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer J Med Chem 2024 67 13019 32 10.1021/acs.jmedchem.4c00998 39077892 Pike KG Hunt TA Barlaam B Benstead D Cadogan E Chen K et al. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390 J Med Chem 2024 67 3090 111 10.1021/acs.jmedchem.3c02277 38306388